

## CURRICULUM VITAE

### **Haiden A. Huskamp**

**Date Prepared:** March 10, 2022

**Office Address:**

Harvard Medical School  
Department of Health Care Policy  
180 Longwood Avenue, Rm 330A  
Boston, MA 02115

**Work Phone:** 617-432-0838

**Work E-Mail:** [huskamp@hcp.med.harvard.edu](mailto:huskamp@hcp.med.harvard.edu)

**Work FAX:** 617-432-0173

**Education:**

1989 B.A. (Honors) Public Policy, Duke University

1997 Ph.D. Health Policy, Economics Concentration, Harvard University

**Faculty Academic Appointments:**

1997-2004 Assistant Professor of Health Care Policy, Department of Health Care Policy,  
Harvard Medical School

2004-2010 Associate Professor of Health Care Policy, Department of Health Care Policy,  
Harvard Medical School

2010-2017 Professor of Health Care Policy, Department of Health Care Policy,  
Harvard Medical School

2017-2020 30<sup>th</sup> Anniversary Professor of Health Care, Department of Health Care Policy,  
Harvard Medical School

2018- Visiting Scholar, Health Policy & Management,  
Johns Hopkins Bloomberg School of Public Health

2020- Henry J. Kaiser Professor of Health Care Policy, Department of Health Care Policy,  
Harvard Medical School

**Other Professional Positions:**

1988-1989 Research Assistant, National Governors' Association, Washington, DC

1989-1990 Program Analyst, U.S. Dept. of Health and Human Services, Washington, DC

1990-1992 Associate, Alpha Center for Health Policy, Washington, DC

### **Harvard Committee Service:**

1994-1999 Member, Board of Freshman Advisors, Harvard College  
1998-1999 Member, Junior Faculty Search Committees, Harvard Medical School  
1999-2001 Member, Committee for Undergraduate Education in Health Policy, Harvard University  
2000-2001 Member, Harvard Health Caucus Advisory Board, Harvard Medical School  
2000- Member, Standing Committee on the Degree of Doctor of Health Policy, Harvard University  
2005-2006 Member, Education Reform Committee on Fundamentals of Medicine, Harvard Medical School  
Co-Chair, Subcommittee on Health Policy and Managerial Sciences  
2006-2007 Member, Center for Population Health Medical Education, Harvard Medical School  
Co-Chair, Subcommittee on Pre-Clinical Education  
2007-2008 Member, Strategic Advisory Group on Education, Harvard Medical School  
2007-2008 Member, Junior Faculty Search Committee, Harvard Medical School  
2009- Member, Curriculum Committee, Harvard Medical School  
Member, Research Compliance Advisory Committee, Harvard Medical School  
2010-2011 Member, Liaison Committee on Medical Education (LCME) Review, Harvard Medical School  
Chair, Ph.D. Program in Health Policy Committee on Fellowships, Harvard University  
2010-2011 Member, Junior Faculty Search Committee, Harvard Medical School  
Member, Faculty of Arts and Sciences Standing Committee on Health, Harvard University Policy  
Member, Safety Committee, Harvard Medical School  
2013- Member, Senior Faculty Search Committee, Harvard Medical School  
2014-2015 Member, Pathways Curriculum Design Committee, Harvard Medical School  
Chair, Social and Population Science  
2015-2016 Member, Junior Faculty Search Committee, Harvard Medical School  
Member, Executive Committee on Higher Degrees in Health Policy, Harvard University  
2017-2020 Member, Advisory Committee on Shareholder Responsibility, Harvard University  
2019- Member, Research Rigor and Reproducibility (R3) Committee, Harvard Medical School  
2020- Chair, Standing Committee on Rights and Responsibilities, Harvard Medical School  
2020- Executive Committee Member, Training in Oncology Population Sciences (TOPS) NCI T32  
Fellowship Program

### **Professional Societies:**

1990- Member, AcademyHealth  
1999- Member, International Health Economics Association  
2006- Member, American Society of Health Economists

### **Grant Review Activities:**

1998 Ad-hoc Grant Reviewer, The Substance Abuse and Mental Health Services Administration,  
*U.S. department of Health and Human Services*  
2002 Ad-hoc Grant Reviewer, Changes in Health Care Financing and Organization (HCFO Program),  
*Robert Wood Johnson Foundation*  
2005 Ad-hoc Reviewer, Study Section Review Panels, *National Institute of Mental Health*

2006 Ad-hoc Reviewer, Health Services Organization and Delivery Study Section, *National Institute of Health*

2010 Ad-hoc Reviewer, Special Emphasis Panel Study Section, *Agency for Healthcare Research and Quality*

2012 Ad-hoc Reviewer, Special Emphasis Panel Study Section, *National Institute of Mental Health*

2013 Ad-hoc Reviewer, R24 Planning Grant Study Section, *National Institute of Mental Health*

2013 Ad-hoc Reviewer, Special Emphasis Panel Study Section, *National Institute of Mental Health*

2015 Ad-hoc Reviewer, Contracts Study Section, *National Institute of Mental Health*

2017 Ad-hoc Reviewer, Fellowships and Dissertation Grants Study Section, *National Institute of Mental Health*

2020 Ad-hoc Reviewer, SERV Conflicts Study Section, *National Institute of Mental Health*

2020 Ad-hoc Reviewer, T32 Study Section, *National Institute of Mental Health*

2021 Ad-hoc Reviewer, RFA Review, *National Institute on Alcohol Abuse and Alcoholism*

**Editorial Activities:**

1997 Ad-hoc Reviewer  
*Journal of Health Economics Inquiry*

1998- Ad-hoc Reviewer, *Health Affairs*

1999 Ad-hoc Reviewer, *Health Care Financing Review*

2000 Ad-hoc Reviewer, *Administration and Policy in Mental Health*

2001- Ad-hoc Reviewer  
*Psychiatric Services*  
*Milbank Quarterly*  
*Journal of Mental Health Policy and Economics*  
*Journal of Economics and Management Strategy*

2002- Ad-hoc Reviewer  
*Medical Care*  
*Health Services Research*

2003- Ad-hoc Reviewer, *Journal of General Internal Medicine*

2004- Ad-hoc Reviewer  
*New England Journal of Medicine*  
*Journal of Health Politics, Policy and Law*  
*Archives of General Psychiatry*

2004- Co-Editor, *Psychiatric Services, Economic Grand Rounds Column*

2006- Ad-hoc Reviewer  
*Pharmacoeconomics*  
*American Journal of Managed Care*

2008- Ad-hoc Reviewer, *Journal of the American Medical Association*

2008-2013 Editorial Board Member, *Medical Care Research and Review*

2011 Ad-hoc Reviewer, *Quarterly Journal of Economics*

2011-2018 Editorial Board Member, *Journal of Pain and Symptom Management*

## **Honors and Prizes:**

- 1992-1994 Trainee, *Agency for Health Care Policy and Research*  
1994-1995 Trainee, *National Institute of Mental Health*  
1996-1997 Fellow, *Alfred P. Sloan Foundation*  
1998-1999 Fellow, *Prudential Health Services*  
2002-2007 Recipient, *National Institute for Mental Health K01 Career Development Award*  
2007-2011 Recipient, *Robert Wood Johnson Foundation Investigator Award in Health Policy Research*  
2012 Recipient, *AcademyHealth Noteworthy Article of the Year*  
2012 Nominee, *Harvard Medical School Donald O'Hara Faculty Prize for Excellence in Teaching (Years I & II)*  
2012 Recipient, *Medical Care Research and Review Best Paper of the Year*  
2013 Nominee, *Harvard Medical School Donald O'Hara Faculty Prize for Excellence in Teaching (Years I & II)*  
2014 Nominee, *Harvard Medical School Donald O'Hara Faculty Prize for Excellence in Teaching (Years I & II)*  
2017 Recipient, *Barbara J. McNeil Faculty Award for Exceptional Institutional Service to Harvard Medical School and Harvard School of Dental Medicine*

## **Report of Funded Projects:**

### **Past**

1995-2000  
Co-Investigator (Richard Frank)  
Brandeis University / National Institute on Drug Abuse  
Grant #U1 P50 DA10233

### **Brandeis/Harvard Center for the Study of Managed Care and Drug Abuse Treatment**

This project examines the choice of organization and contract structure of managed behavioral health care and estimates the response to contract features for a set of public and private insurance contracts.

---

1998-1999  
Principal Investigator  
Center for Health Care Strategies, Inc./The Robert Wood Johnson Foundation  
Grant #ML 375

### **Procurement Strategies for Medicaid Managed Care Programs Serving Individuals with Chronic and Disabling Conditions**

This study examines state and country strategies for the procurement of Medicaid managed care contracts to serve individuals with chronic and disabling conditions.

---

1998-1999

Research Fellow (Barbara McNeil)

Prudential Health Services Research Fellowship

The Effects of Managed Mental Health Care

This project fosters collaboration between Prudential and Harvard and provides an opportunity for postdoctoral fellows and junior faculty to gain experience in health services research, and particularly in issues pertaining to managed care.

---

1999-2001

Co-Investigator (Richard Frank)

Eli Lilly Foundation

Managed Care and Therapeutic Choice

This project examines the impact of benefit design (patient incentives), vendor contract provisions (managed care organization incentives), and provider payment, organization and contract features (provider incentives) on treatment choice for depression, anxiety disorder, and alcohol abuse.

---

1999-2006

Co-Investigator (Joseph Newhouse)

Alfred P. Sloan Foundation

Grant #98-12-7

Managed Care Industry Center

This grant funds the core of the Harvard Managed Care Industry Center. The purpose of the center is to train new researchers on the industry and to initiate collaborative studies to improve industry performance and to identify best practices. The Center's research focus is on the effects of risk-sharing on quality and outcomes of care for both managed care and managed behavioral health care.

---

2000-2002

Principal Investigator

Robert Wood Johnson Foundation

Grant #036415

The Impact of Medicare Financing Methods on End-of-Life Care

This study examines how different actors involved with providing end-of-life services perceive the strengths and limitations of the current Medicare financing system. In addition, the project explores the implications for future Medicare policy of the issues raised and ways in which the Medicare financing system might be changed to address any problems identified.

---

2000-2004

Co-Investigator (Richard Frank)

Northrop Grumman Corp. / DHHS

Grant #S-26027

Evaluation of Parity in the Federal Employees Health Benefits Program

For this study evaluating the effects of requiring parity in coverage of mental health and general medical care services within the Federal Employees Health Benefits Program, the Harvard research team will have lead responsibility for constructing all analysis files based on administrative data for all analyses related to costs, utilization, access and quality. The Harvard team will also have responsibility for analysis of costs and utilization data in both the administrative data sets and for the survey research data. Harvard investigators will also participate in the survey design and analysis of patient satisfaction data. Members of the Harvard team will also work on health plan reviews, focus groups and site visits at OPM and eight health plans. Harvard investigators will be involved in the overall evaluation design, the writing of reports of findings and progress of the research. Harvard will also have responsibility for providing the government with analysis files and detailed documentation.

---

2000-2005

Co-Investigator (Richard Frank)

Robert Wood Johnson Foundation

Grant #039960

Organization and Financing of Primary Care Depression

The goal of this activity is to develop a set of economic incentives and organizational arrangements that support recent advances in the understanding of how depression is most effectively treated in a primary care context. Pursuing this overall goal requires engaging in a number of specific activities aimed at developing and specifying the economic model. There are five main activities: 1) Conduct a review of the literature on treating depression in primary care to identify what has been learned about how the economic and organizational context promote or hinder the effective treatment of depression. 2) Examine secondary data sets to identify common treatment patterns for depression in primary care. 3) Identify and familiarize ourselves with innovative treatment programs aimed at depression in the primary care setting. 4) Analyze the incentives and the organizational structures that promote adherence to appropriate clinical choices. 5) Specify a set of economic and organizational principles to be used in developing a demonstration program.

2001-2004

Co-Investigator (Richard Frank)

Robert Wood Johnson Foundation

Grant #42094

Impact of Incentive Formularies on Prescription Drug and Health Care Costs and Utilization

The fundamental question of how to balance costs, choice of drugs and innovations in the prescription drug area has become one of the more pressing challenges facing the management of health plans. We will trace the diffusion formulary arrangements and analyze factors that influence an employer's or managed care organization's (MCO) decision to use three-tiered formularies and other patient incentive arrangements. Descriptive and multivariate analysis will be used to study the importance of various factors on employer/health plan choices. This study will provide important information for both public and private policymakers on the impacts of one of the new private sector methods of managing pharmaceutical benefits on prescription drug use, pharmacy and total health care spending, and patterns of care.

---

2000-2005

Co-Investigator (Joseph Newhouse)

Agency for Healthcare Research and Quality

Grant #5 P01 HS10803

Structuring Markets and Competition in Health Care

This Program Project will develop and apply an overarching conceptual framework, drawn from economic theory, for understanding the roles of purchasers, plans, providers, and patients in a market environment characterized by which payers contract with health plans and plans by capitation. Managed care greatly expands the dimensions upon the market structure itself, which determines how payers, plans, and providers both contract and compete with each other. Alternative market structures have different effects on costs and clinical endpoints. Our Program Project will improve understanding of these effects. The R01 led by Dr. Huskamp examines two types of benefit carve-out arrangements (pharmacy carve-outs and mental health and substance abuse (MHSA) carve-outs) and explores their impacts, including any cost shifting that resulted from use of carve-outs.

---

2004

Principal Investigator

Henry J. Kaiser Family Foundation

Grant #02-1237-600

Analysis of the New Medicare Prescription Drug Law

This project analyzes the key features of the Medicare Modernization Act of 2003 and discusses implications of these features for cost, access, and quality of care for Medicare beneficiaries.

---

2004-2006

Principal Investigator

Technical Assistance Collaborative / MacArthur Foundation

Grant #03-78360-000-HCD

Variations in Quality of Depression Treatment among Specialty Mental Health Providers

This study uses claims data from a large managed behavioral health care organization to examine the provision of quality care within a network of specialty mental health providers.

---

2005-2007

Co-Investigator (Meredith Rosenthal)

Robert Wood Johnson Foundation

Grant #056107

Uptake and Impact of Health Risk Appraisals

Efforts to inform and motivate consumers to make better health and health care choices have diffused throughout the health care market. One of the central components of these consumer health management programs is the health risk appraisal (HRA). HRAs are structured surveys designed to identify a wide range of health risks, including genetic predispositions to disease, poor health habits, and lack of adherence to recommended care for a chronic condition. In this study, we explore the potential of HRAs to engage consumers in health improvement. In particular, we will examine the overall rates of HRA completion in a privately-insured population, the impact of a consumer financial incentive on HRA completion, the characteristics of consumers who opt to complete an HRA, and early effects of HRAs on utilization and health behavior.

---

2002-2008

Principal Investigator

National Institute of Mental Health

Grant #K01 MH66109

Economics of Formulary Design and Mental Health Policy

This Mentored Research Scientist Development Award would allow Dr. Haiden Huskamp, a health economist with expertise in mental health policy and economic institutions, to supplement her economic tools with the knowledge and skills needed to conduct clinically-relevant and policy-significant research on the economics of prescription drugs used in the treatment of mental illnesses. The specific aims of this career development proposal are to: 1) develop a greater understanding of clinical decision making related to the use of psychotropic



drugs; 2) acquire basic knowledge of psychopharmacology; and 3) expand knowledge of the important economic institutions influencing the prescription drug market. In this undertaking, Dr. Huskamp will be guided by her sponsor, Richard Frank, PhD, and co-sponsors, Andrew Nierenberg, MD, and Ernst Berndt, PhD.

---

2008-2009

Principal Investigator

Charles H. Farnsworth Trust, \$54,529

Hospice Utilization among Terminally Ill Nursing Home Residents in New England Communities

Using data from a large regional hospice serving nursing home residents in five New England states and data on nursing home characteristics and quality of care, we will document the variation in timing of hospice referral across nursing homes, identify patient characteristics and nursing home characteristics that are associated with earlier referral to hospice, and examine whether nursing homes that provide higher quality nursing care are more likely to make earlier referrals to hospice.

---

2005-2008

Co-Investigator (Sharon-Lise Normand)

National Institute of Mental Health

Grant #R01 MH061434

Modeling Treatment Use & Effectiveness in Mental Health

This application seeks continued support for a team of statisticians, economists, and clinicians to collaborate on the development and application of longitudinal hierarchical discrete choice models for understanding diffusion of mental health technologies and for causal inference. Dr. Huskamp does not have any effort budgeted for year two of this project. This project has a no-cost extension thru 7/31/09.

---

2008-2009

Co-Investigator (John Ayanian)

National Cancer Institute

Grant #U01 CA093324

Cancer Care Outcomes Research & Surveillance Consortium (CanCORS)

The objectives of the CanCORS initiative are to: 1) enhance monitoring and understanding of the processes of cancer care and patient-centered factors influencing prognosis in population-based cohorts of lung and colorectal cancer patients; 2) establish a system for examining the relationship of the processes of care to clinical and patient-centered outcomes, with emphasis on measuring the dissemination of state-of-the science interventions and their association with better quality outcomes in the general population of cancer patients; and 3) examine

disparities in the receipt of state-of-the-science cancer care and factors that contribute to disparities in outcomes and identify ways to lessen those disparities. This project is in a no cost extension phase.

---

2009-2010

Multiple PI

Medicare Payment Advisory Commission, \$43,682 (MedPAC)

Contract # E4058946

Medicare Part D, Long-term Care Pharmacies, and Nursing Facilities

To assess the impact of Part D in the nursing home setting, we will conduct interviews of key stakeholders on the impact of Part D on medication access, care delivery, and quality of care outcomes for nursing home residents.

---

2007- 2011

Principal Investigator

Robert Wood Johnson Foundation Investigator, \$252,901

Award in Health Policy Research Program

Grant #60468

Has the Revolution Come and Gone? The Societal Value of New Psychotropic Drugs

The past two decades were a period of rapid development of new drug treatments for mental illness. Some believe these new drugs have brought about “revolutionary” changes in the treatment of mental illness. At the same time, the growth in psychotropic drug costs has been explosive. Rapid cost increases combined with high accounting profits have brought increased scrutiny to drug manufacturers over whether the drugs they produce are worth the costs. This project will compare the social costs and benefits of newer psychotropic drugs to assess their social value and then identify ways that the value of psychotropic drug spending can be increased.

---

2008-2011

Principal Investigator

National Institute of Mental Health, \$663,553

Grant #R01 MH080797

Effects of Mental Health Parity on High-Cost and Severely-Ill Individuals

Mental health parity policies aim to protect individuals with severe mental illnesses against the catastrophic costs of seeking treatment, and, in doing so, increase efficiency and fairness in the insurance market. In 2001, all plans participating in the Federal Employees Health Benefits (FEHB) Program were required to offer coverage for MH/SA services on a par with general medical services. This study will: 1) assess whether

individuals with high MH/SA expenditures disproportionately benefited from the comprehensive FEHB parity policy, 2) compare characteristics of high spenders before and after parity adoption, and 3) examine how parity affected the composition, intensity, and quality of treatment received

---

2010-2013

Co-Investigator

Agency for HealthCare Research and Quality

Grant # R01 HS018960

Assessing the Effect of FDA Advisories on Psychotropic Medications

This project will assess the impact of FDA safety advisories and black box warnings on prescription drug utilization by patients and physician prescribing patterns for three classes of psychotropic medications (antidepressants, antipsychotics, and stimulants).

---

2010-2013

Co-Investigator

National Institutes of Health

Grant # 1RC4MH092717

Accounting for Confounding Bias and Heterogeneity in Comparative Effectiveness

This proposal seeks to develop novel and generalizable methods for addressing these problems. Specifically, we will develop novel approaches for combining data from randomized trials, registries and/or claims-based data (taking advantage of the strengths of both RCT and observational data); extend the latest techniques for instrumental variable analysis; and develop novel simultaneous equation models to account for confounding that are less sensitive to assumptions than currently-used methods. In so doing, we will apply these methods to three important clinical examples: treatments for bipolar disorder for patients with psychiatric comorbidity, reformulations of existing psychiatric drug treatments, and the surgical repair for abdominal aortic aneurysm (AAA).

---

2009-2014

Co-Investigator

National Institute on Aging

Grant #PO1 AG032952

The Role of Private Plans in Medicare

The Program Project intends to undertake a fundamental examination of the economics of Medicare Part C, or Medicare Advantage (MA) from a framework grounded in economic theory. The Project is organized around five integrated component projects studying: 1) The factors influencing beneficiary choice of MA plan or

traditional Medicare (TM); 2) How MA plans decide about entry and choose the overall generosity of benefits, depending upon Medicare payment policy; 3) Plans' choice of the mix or structure of their benefits in light of possible opportunities for efficiencies from integration and incentives for selection due to imperfect risk adjustment; (4) The consequences (spillovers) of plan choices about entry and practice patterns for beneficiaries in TM and non-Medicare populations; and 5) The design optimal payment, regulatory, and informational policies for Medicare to set for MA plans.

---

2009-2014

Principal Investigator

National Institute on Aging, \$855,595

Grant #R01 AG034085

#### Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents

This study will examine the effect of Medicare Part D drug plan generosity on medication use and health outcomes for dual-eligible nursing home residents. We will combine drug utilization data from a large long term care pharmacy, data on health outcomes from the Minimum Data Set (MDS), and Medicare Part A hospitalization claims for the period 2005-2008.

---

2009-2014

Consortium PI

Harvard Pilgrim Health Care / AHRQ, \$120,027

Grant #R01 HS018577-01

#### Drug Cost Containment Changes and Quality of Care for Mentally Ill Dual Enrollees

This study will examine the impact of the shift from Medicaid drug coverage to Medicare Part D among dual eligibles with schizophrenia or bipolar disorder.

---

2013-2015

Multi-PI

Commonwealth Fund, \$178,011

Grant # 20130499

#### Impact of Accountable Care Organization Models with Risk Based Payments on Individuals with Mental Illness

This study assesses the effect of accountable care organization models on mental health service use and spending, and on total health care spending for individuals diagnosed with a mental illness, including those with multiple co-morbidities.

---

2013-2014

Co-Investigator

Laura and John Arnold Foundation

Health Care Markets and Regulation Lab: Seed Funding

Overall objective: To help the U.S. healthcare system move forward by providing critical evidence, analyses and tools necessary to design health care regulations and markets to promote high quality care and innovation at a sustainable cost. Initial phase (seed) objectives include: (1) establish an organizational and governance structure, (2) set priorities within and between program areas, and (3) identify feasible, transformative projects

---

2012-2016

Multi-PI National Institute of Mental Health, \$ 1,172,397

Grant #R01 MH093359

Influences on Psychiatrist Prescribing of Antipsychotics

This project examines the factors that influence the speed with which psychiatrists adopt new antipsychotics and respond to new evidence on their comparative effectiveness and safety, including organizational factors, commercial influences, and policy levers.

---

2014-2016

Co-Investigator

DHHS/Office for the Asst. Secretary for Planning and Evaluation (ASPE)

Healthcare Integration in Medicare Accountable Care Organizations

Using both quantitative and qualitative methods, this project will examine the impact of Accountable Care Organizations (ACOs) in Medicare on behavioral health care and outcomes and explore the extent to which ACOs target behavioral health conditions for value-enhancing changes in care management.

---

2012-2016

Co-Investigator

National Cancer Institute

Grant # R01CA164021

Explaining Variations in End-of-Life Care Intensity

This study will expand our understanding of the factors contributing to the high expenditures and intensity of end-of-life (EOL) care for individuals with advanced cancer and will help to identify the appropriate targets for strategies to address disparities in EOL care. If differences in EOL care intensity are primarily driven by physicians, local area practice patterns, and availability of services (e.g., intensive care beds), the findings will identify opportunities for interventions to assure that patients obtain care at the EOL that matches their preferences, and it will identify opportunities to decrease intensity of care in areas where such care is not driven by patients' preferences. If high-intensity EOL care is driven by patients' preferences, then it will be important to assess if these are informed preferences and, if not, whether they can become informed preferences (e.g., preferences that may be modifiable through EOL discussions).

---

2014-2016

Co-Investigator

American Cancer Society/University of North Carolina

Impact of Parity Legislation on Use and Costs of Oral Cancer Medications

Capitalizing on a natural experiment, we will use national health insurance claims data to estimate the impact of oral cancer medication parity legislation on the use and spending for cancer therapies. We will use a difference-in-difference-in-difference modeling strategy to examine care before and after parity legislation in states that did and did not adopt parity legislation, and among patients who are or are not enrolled in self-insured plans that are exempt from state-level legislation. Analyses will focus on changes in overall and proportional use of oral cancer therapies (Aim 1); changes in spending on cancer treatment for patients and insurers (Aim 2); and changes in adherence to oral cancer medications (Aim 3).

---

2015-2016

Co-Investigator

Vanderbilt University Sub u/d ASPE, \$43,897

Tracking the Impact of Ownership Changes in Hospice Care Provided to Medicare Beneficiaries

This project will examine hospice ownership and the impact of ownership changes on hospice utilization for Medicare beneficiaries at the end of life.

---

2012-2017

Co-Investigator

National Institute of Mental Health, \$159,671

Grant # R01 MH093414

## Implementation of Federal Mental Health Parity

In October 2008, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity (MHPAE) Act was passed by the U.S. Congress. This law is the culmination of a decades-long effort to achieve comprehensive federal insurance parity. Advocates have raised concern related to how certain diagnoses and treatments will be covered under the law. Also, employers and health plans have indicated apprehensions about extending parity to out-of-network (OON) services. This study examines the effects of these specific provisions of the law.

---

2014-2017

Principal Investigator

National Cancer Institute, \$270,500

Grant # R21 AG047175

## Comparative Effectiveness of Treatment Regimens in Lung Cancer

In this study, we compare the morbidity and mortality of elderly Medicare patients with newly diagnosed extensive stage small cell cancer (ES SCC) ES SCL according to which one of the two standard first-line chemotherapy regimens they received. To do this, we apply sophisticated analytic methods (including propensity scores) to a Medicare-based data source to identify and then match elderly Medicare patients with ES SCLC who received the combination of drugs “cisplatin-etoposide” as first-line treatment of their cancer to otherwise similar elderly Medicare patients with ES SCLC who received a different combination of drugs “carboplatin-etoposide” as first-line treatment of their cancer. The results will be important to the field of comparative effectiveness research through our treatment of hospital-based health care (e.g., emergency room visits, hospitalizations, and intensive care use) as morbidity (i.e., a “toxicity” or “burden”). The results will also be immediately relevant to clinical geriatric oncology through provision of estimates of risk and benefit according to treatment and in so doing aid in patient-oncologist decision-making.

---

2013-2018

Multi-PI

National Institute on Drug Abuse, \$1,585,657

Grant #R01 DA035214

## Substance Use Disorder Treatment under New Payment and Delivery System Models

This study assesses the effect of global payment and accountable care as implemented through the Blue Cross and Blue Shield of Massachusetts’ Alternative Quality Contract (AQC) initiative on changes in use, price, spending, and performance measures for substance use disorder (SUD) and nicotine dependence services.

---

2013-2018

Co-Investigator

University of Pittsburgh / NHLBI, \$103,928

Grant # R01 HL119246

The Role of Physician Networks in the Adoption of New Prescription Drugs

This project would link data from multiple sources to: 1) examine the association at the regional-level between physician adoption of new drugs that treat cardiovascular disease (CVD), and CVD medication use and spending, and non-drug medical spending, and 2) examine the influence of physician characteristics and multiple types of professional networks on physician adoption of new CVD medications.

---

2014-2017

Co-Investigator

Laura and John Arnold Foundation

Health Care Markets and Regulation Lab

Overall objectives: (1) Initiate specific, innovative, high impact projects that have the potential to meaningfully support the transformation of the American Health Care system. Research areas include: quality measurement, payment and delivery system reform, consumer behavior, risk adjustment and exchanges. (2) Develop core resources to support the aforementioned projects, move forward on existing work and enhance the visibility and impact of lab activities.

---

2017-2018

Multi-P.I.

Vanderbilt University Medical Center/ASPE, \$57,734

(Contract # HHSP233201700036C)

Trends in Nursing Home-Hospice Contracting and Common Ownership between Hospice Agencies and Nursing Homes

This project will explore the dynamics of nursing home-hospice contracting and how it has evolved over time. A key focus of the research is to explore implications of joint ownership between hospice agencies and nursing homes.

---

2013-2019

Multi-PI

NIH/NIMH, \$1,606,288

Grant # U01 MH103018



### Technology Diffusion Pathways

This study will conduct an in-depth investigation of the patterns of diffusion of new technologies, including drugs, biologics, and devices, across organizations of different types, and assess the effects of a new model for organizing and financing health care that is encouraged under the Affordable Care Act (ACA) of 2010 – risk-based payments made to accountable care organizations (ACOs) – on spending for new technologies.

---

2017-2020

Co-Investigator

Laura and John Arnold Foundation

Health Care Markets and Regulation Lab

Overall objectives: (1) Initiate specific, innovative, high impact projects that have the potential to meaningfully support the transformation of the American Health Care system. Research areas include: quality measurement, payment and delivery system reform, consumer behavior, risk adjustment and exchanges. (2) Develop core resources to support the aforementioned projects, move forward on existing work and enhance the visibility and impact of lab activities

---

2019-2020

Multi-P.I.

March Of Dimes, \$90,866

### The Affordable Care Act and Low-Income Women.

This project will assess the impact on low-income women of losing coverage obtained under the Affordable Care Act.

---

2018-2020

Co-Investigator

Vanderbilt University Medical Center Sub u/d Commonwealth Fund

### Identifying Cost and Coverage Barriers to Medicare Beneficiary Access to Specialty Drugs

This study will describe recent trends in prices, Medicare Part D plan coverage, and cost sharing requirements for specialty drugs. The study will also identify rates of and factors associated with never filling, or experiencing delays in filling, prescribed specialty medications

---

2015-2021

Co-Investigator

Brandeis University/ National Institute on Drug Abuse

(Grant # P30 DA035772)

Center to Improve System Performance of Substance Use Disorder Treatment

The Center will use research on payment methods and service delivery approaches to expand the research base on improving substance use disorder (SUD) care quality and reduce the cost of health care services, and to inform policy decisions that will profoundly affect the cost, quality and availability of SUD treatment services.

---

2017-2020

Multi-P.I.

Vanderbilt University Medical Center/ASPE, \$103,709

(Contract # HHSP233201700050C)

Opioid Use in Nursing Homes

This project will examine recent trends in opioid prescribing among nursing home residents.

---

2018-2020

Co-Investigator

Vanderbilt University Medical Center Sub u/d Leukemia and Lymphoma Society

Identifying Cost and Coverage Barriers to Medicare Beneficiary Access to Specialty Drugs

This study will describe recent trends in prices, Medicare Part D plan coverage, and cost sharing requirements for specialty drugs. The study will also identify rates of and factors associated with never filling, or experiencing delays in filling, prescribed specialty medications

---

**Current:**

2019-2023

Multi-P.I.

NIH/NIDA, \$597,027

(Grant # R01 DA048533)

Telemedicine for Treatment of Opioid Use Disorder

This project is a comprehensive evaluation of telemedicine for opioid use disorder using Medicaid, Medicare, and commercial insurance data as well as a series of qualitative interviews.

---

2018-2022

Co-Investigator      Johns Hopkins University / NIDA, \$63,679

(Grant # R01 DA044201)

Consumer-Directed Health Plans and Substance Use Disorder Treatment

This project will examine the impact of the shift toward consumer-directed health plans on use of substance use disorder treatment services.

---

2017-2021

Co-Investigator

National Institute of Mental Health

(Grant # R01 MH112829)

Impact of Telemedicine on Medicare Beneficiaries with Mental Illness

Access to mental health specialists is difficult for many patients in the U.S., particularly for the poor and those who live in rural communities. Telemental health is one potential solution for this access problem. In the proposed project we will conduct a series of descriptive analyses to understand how telemental health is being used and whether communities with greater telemental health penetration have experienced improvements in care for patients with mental illness.

---

2020-2022

Co-Investigator

(Grant # 20202697) \*co-funded

The Commonwealth Fund (via VUMC)

Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending

We will document drug list and net price trends in Medicare and examine the relationship between average rebate size and Part D formulary placement, beneficiary cost sharing, and product market share within a drug class. We will also assess trends in list and net prices for Part D drugs after generic competition occurs and whether drugs with large rebates have more generous formulary coverage and less use of generic alternatives. Finally, we will explore pricing dynamics and market share for authorized generics (i.e., exact copies of branded drugs that exclude the brand name from packaging), including their use relative to traditional brands and traditional generics for the same product.

---

2020-2022

Co-Investigator

(Grant # 20-04272) \*co-funded

Arnold Ventures (via VUMC)

## Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending

We will document drug list and net price trends in Medicare and examine the relationship between average rebate size and Part D formulary placement, beneficiary cost sharing, and product market share within a drug class. We will also assess trends in list and net prices for Part D drugs after generic competition occurs and whether drugs with large rebates have more generous formulary coverage and less use of generic alternatives. Finally, we will explore pricing dynamics and market share for authorized generics (i.e., exact copies of branded drugs that exclude the brand name from packaging), including their use relative to traditional brands and traditional generics for the same product.

---

2021-2025

Multi-P.I.

NIH/NIAAA \$2,867,465

(Grant # 1R01AA029267)

## Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories

Many individuals with alcohol use disorder (AUD) receive no treatment, including evidence-based medications. This study, using linked electronic health record data on medication orders and claims data (combined with qualitative methods), will allow more precise identification of where individuals fall off the path of AUD medication use.

---

## **Report of Local Teaching and Training**

### **Teaching of Students in Courses:**

- 1999-2005 HC704 Introduction to Health Care Policy  
Co-Director  
Approximately 25 first-year medical students  
Harvard Medical School, 1 two-hour session p/week for 14 weeks
- 2007-2009 HC750 Health Care Policy  
Co-Director  
140 second-year medical students  
Harvard Medical School, 1 two-hour session p/week for 14 weeks
- 2010-2015 HC750 Health Care Policy  
Co-Director  
140 first-year medical students  
Harvard Medical School, 5 two-hour sessions p/week for 4 weeks
- 2016-2017 Essentials of the Profession: Evidence, Ethics, Policy, and Social Medicine

Co-Director  
170 first-year medical and dental students  
Harvard Medical School, 12 two-hour sessions

2019-  
Essentials of the Profession  
Small Group Leader  
10-12 first-year medical and dental students  
Harvard Medical School, 8 one-hour sessions

**Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):**

1997-  
Doctoral Seminar in Health Care Policy  
Harvard University Ph.D. Program in Health Policy  
20-25 first-year doctoral students in Health Policy  
1-4 lectures per year

1997-  
Doctoral Seminar in Health Economics  
Harvard University Ph.D. Program in Health Policy  
2-8 second-year doctoral students in Health Economics  
1-2 lectures per year

2000-2001  
Introduction to Health Care Policy  
Kennedy School of Government  
25-30 masters' students in Public Policy  
1 lecture per year

2004-2006  
Introduction to the U.S. Health Care System  
Cambridge Hospital Integrated Clerkship Program  
8-10 clerkship students  
1 lecture per year

2005-2006  
Introduction to Health Care Policy  
Beth Israel Deaconess Medical Center—Fellowship in Geriatric Medicine  
8 fellows  
3 lectures per year

2007  
Medicare, Medicaid and Rising U.S. Health Care Costs  
Harvard Medical School/Brigham and Women's Hospital—Patient-Doctor III Tutorial  
12-15 third-year medical students  
1 lecture

2009-2010  
Principal Investigator  
Ongoing mentoring sessions

	NIMH Pre- and Post-Doctoral Training Grant #T32MH019733 4 pre-doctoral and 2 post-doctoral trainees
2009	Pre- and Post-doctoral Seminar in Mental Health Policy 10 sessions 4 pre-doctoral and 2 post-doctoral trainees
2011	Private Health Insurance Partners HealthCare 15-30 resident physicians
2016	Mental Health Policy Harvard School of Public Health 1 lecture 40-50 masters' students
2018-	Principal Investigator Ongoing mentoring NIMH Pre- and Post-Doctoral Training Grant #T32MH019733 4 pre-doctoral and 2 post-doctoral trainees
2018	Steering Committee Member Ongoing mentoring NCI Training in Oncology Population Sciences (TOPS) #T32CA09220317 3 post-doctoral trainees
2019	Mental Health Policy (HLTHPOL3002) Graduate School of Arts and Sciences 10 sessions 10-12 graduate and undergraduate students
2021	Mental Health Policy (HLTHPOL3002) Graduate School of Arts and Sciences 10 sessions 10-12 graduate and undergraduate students

**Formally Supervised Trainees and Faculty:**

1997-2000	Susan Busch, Ph.D. Professor, Dept. of Health Policy & Management
-----------	--

Yale University School of Medicine

*Dissertation Committee Member—Supervised completion of three dissertation essays and two papers in peer reviewed journals*

2000-2002

David Auerbach, Ph.D.  
Policy Researcher, RAND

*Dissertation Committee Member—Supervised completion of three dissertation essays*

2001-2004

Colleen Barry, Ph.D.  
Fred and Julie Soper Professor and Chair  
Johns Hopkins Bloomberg School of Public Health  
Dept. of Health Policy and Management

*Dissertation Committee Member—Supervised completion of three dissertation essays and three papers in peer reviewed journals*

2001-2002

Andrea Magyera  
Current position unknown

*Undergraduate Thesis Advisor for Harvard College—Supervised completion of senior thesis*

2002-2004

Laura Eselius, Ph.D.  
Senior Fellow  
Deloitte Research

*Dissertation Committee Member—Supervised completion of three dissertation essays and one paper in peer reviewed journal*

2003-2005

Stephanie Shimada, Ph.D.  
Research Assistant Professor of Health Policy and Management  
Boston University

*Dissertation Committee Member—Supervised completion of three dissertation essays and one paper in peer reviewed journal*

2004-2007

Yuting Zhang, Ph.D.  
Associate Professor  
University of Pittsburgh, School of Public Health

*School of Public Health Dissertation Committee Member—Supervised completion of three dissertation essays and three papers in peer reviewed journals*

- 2007-2009 Katy Backes Kozhimannil, Ph.D.  
Professor  
University of Minnesota School of Public Health  
*Dissertation Committee Co-Chair—Supervised completion of three dissertation essays and two papers in peer reviewed journals (thus far)*
- 2008 Samuel Kina  
Associate, Analysis Group  
*Dissertation Committee Member*
- 2008-2009 Jennifer Polinski  
Director  
Foundational Research  
*CVS Caremark Corporation Dissertation Committee Member -- Supervised completion of three dissertation essays (student currently on maternity leave)*
- 2008-2009 Kyle Gibler  
Current Position Unknown  
*Undergraduate Thesis Advisor for Harvard College—Supervised completion of senior thesis and one paper in peer-reviewed journal*
- 2009 Marguerite Burns, Ph.D.  
Associate Professor  
University of Wisconsin-Madison School of Medicine and Public Health  
*NIH K01 Career Development Award Mentor*
- 2010 Meredith Chace  
Current Position Unknown  
*Dissertation Committee Member*
- 2010-2011 Sara Toomey, M.D.  
Assistant Professor in Pediatrics  
Harvard Medical School, Boston Children's Hospital  
*NIH K01 Career Development Award Application Mentor*



- 2010-2012      Stacie Dusetzina, Ph.D.  
Associate Professor  
Vanderbilt University
- Supervised Post-Doctoral Fellowship in Mental Health Policy Research*
- 2013-2015      Kirstin Scott, M.D., Ph.D.  
Medical Resident  
University of Michigan
- Dissertation Committee Member*
- 2015-2016      Savannah Bergquist, Ph.D.  
Post Doctoral Fellow  
Stanford University
- Advisor*
- 2016              Yuhua Bao, Ph.D.  
Associate Professor  
Weill Cornell Medicine
- Member of Mentoring Committee*
- 2016              Kelsey Berry, Ph.D.  
Post Doctoral Fellow  
Harvard University
- Dissertation Committee Chair*
- 2018-2020      Bryan Buckley, Sc.D.  
Student  
Harvard School of Public Health, DrPH Program
- Dissertation Committee Member*
- 2019-            Rebecca Stewart, Ph.D.  
Research Associate  
University of Pennsylvania Perelman School of Medicine
- K23 Mentor*

## **Report of Regional, National and International Invited Teaching and Presentations**

1996 Atlanta, GA	Managed Behavioral Health Care Carve-outs in the Private Sector	Presented original research Association for Health Services Research Annual Meeting
1996 Bethesda, MD	Risk Sharing Schemes in Managed Behavioral Health Care and the Incentives They Create	Presented original research National Institute of Mental Health Biennial Research Conference of the Economics of Mental Health
1997 Chicago, IL	Empirical Clues about the Consequences of Parity Legislation under Managed Care	Presented original research Association for Health Services Research Annual Meeting
1998 Bethesda, MD	Empirical Clues about the Consequences of Parity Legislation under Managed Care	Presented original research National Institute of Mental Health Biennial Research Conference of the Economics of Mental Health
1998 Washington, DC	Managed Care Incentives and Substance Abuse Treatment	Presented original research American Public Health Association Annual Meeting
1999 Rotterdam, Netherlands	Financial Incentives and the Treatment of Depression	Presented original research International Health Economics Association Biennial Conference
1999 San Francisco, CA	A Partnership to Study Financial Incentives, Mental Health and Substance Abuse Treatment and Workplace Performance	Invited panelist Business for Social Responsibility Annual Conference
2000 Washington, DC	The Medicare Prescription Drug Benefit: How Will the Game Be Played?	Invited panelist National Health Policy Forum

2000 Atlanta, GA	Medicare Financing of End-of-Life Care: Issues Raised by Providers and Suggestions for Change	Presented original research American Academy of Hospice and Palliative Medicine Annual Assembly
2000 Worcester, MA	The Economics of Mental Health	Presented educational lecture Massachusetts State Area Medical Directors
2000 New York, NY	Providing Care at the End of Life: An Assessment of Medicare Coverage and Reimbursement	Invited presenter Project on Death in America Advisory Board Meeting
2000 New York, NY	Providing Care at the End of Life: An Assessment of Medicare Coverage and Reimbursement	Presented original research First International Geriatric Palliative Care Congress
2000 Denver, CO	Economics of Mental Health	Presented educational lecture Harvard University/National Association of State Mental Health Program Directors Executive Training Program
2001 New Orleans, LA	Moving Market Share: Drug Formularies and Demand Elasticity	Presented original research American Economics Association Annual Meeting
2001 York, England	Carve-outs and Cost Shifting	Presented original research International Health Economics Association Biennial Conference
2001 Arlington, VA	Reference Pricing	Presented original research International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting
2001 Bethesda, MD	What is Known about the Economics of End- of-Life Care for Medicare Beneficiaries?	Presented original research National Institutes of Health Integrative Workshop on End-of- Life Research
2002	Economics of Drug Formularies	Presented original research

Bethesda, MD		National Institute of Mental Health Pharmacoeconomics Research Workshop
2002 Cambridge, MA	Economics of Three-Tier Formularies	Invited presenter Harvard Medical School Conference on Health Economics in Managed Care
2002 Charlottesville, VA	Basics of Mental Health Economics	Invited presenter American Psychiatric Association Board of Trustees Retreat
2002 Denver, CO	Economics of Mental Health	Presented educational lecture Harvard University/National Association of State Mental Health Program Directors Executive Training Program
2003 Venice, Italy	The Impact of Three-tier Formularies on Prescription Drugs Used by Patients with Mental Illness	Presented original research International Center of Mental Health Policy and Economics Workshop on Costs and Assessment in Psychiatry
2003 Boston, MA	Economics of Three-tier Formularies	Invited presenter Boston University/Harvard University/Massachusetts Institute of Technology Joint Seminar on Health Economics
2003 Chicago, IL	Impact of Three-tier Formularies on Cost and Utilization Patterns	Invited presenter University of Chicago Harris School of Public Policy
2003 Chicago, IL	Impact of Incentive Formularies on Drug Utilization and Spending	Presented original research American Statistical Association International Conference on Health Policy Research
2003 Phoenix, AZ	Formulary Use in the Treatment of Depression	Invited presenter The Robert Wood Johnson

		Foundation's Annual Meeting of the Depression in Primary Care Program
2003 York, NY	Future Research Directions in Pediatric Palliative Care: Financing and Economics	Presented original research New York Academy of Medicine, Initiative for Pediatric Palliative Care National Symposium
2003 Boston, MA	The Impact of Incentive Formularies	Invited presenter Harvard Medical School Conference on Health Economics in Managed Care
2004 New Haven, CT	The Impact of Three-Tier Formularies on Drug Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children	Invited presenter Yale University
2004 Waltham, MA	The Impact of Three-Tier Formularies on Drug Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children	Invited presenter Brandeis University
2004 Washington, DC	The New Medicare Drug Benefit: Potential Effects of Pharmacy Management Tools on Access to Medications	Invited presenter Henry J. Kaiser Family Foundation
2004 Chicago, IL	The Impact of Three-Tier Formularies on Cost and Patient Compliance	Presented original research Institute for International Research Pharmacy Cost Management Conference
2004 Washington, DC	The Impact of Three-Tier Formularies on Drug Treatment of ADHD in Children	Presented original research National Institute of Mental Health Twelfth Biennial Research Conference on the Economics of Mental Health
2004 Philadelphia, PA	Formularies and Cost Sharing Issues for Medicare Part D	Invited presenter The Robert Wood Johnson Foundation's State Coverage Initiatives' Invitational Summit for State Policy Makers on

		Medicare Part D Implementation Issues
2005 Washington, DC	The Effect of Three-Tier Formulary on Medication Continuation and Spending Among Elderly Retirees	Invited presenter RAND Health
2005 Bethesda, MD	Medicare Modernization Act and Prescription Drug Pricing	Presented original research National Institute of Mental Health Third Pharmacoeconomics Workshop
2005 Cambridge, MA	The Impact of Parity Mental Health and Substance Abuse Benefits in the Federal Employees' Health Benefits Program	Invited presenter Mathematica Policy Research
2005 Boston, MA	The Effect of Three-Tier Formulary Adoption on Medication Continuation and Spending Among Elderly Retirees	Presented original research AcademyHealth Annual Research Meeting
2005 Boston, MA	Medicare Modernization Act: The Impact of State Implementation Decisions	Presented original research AcademyHealth Annual Research Meeting
2005 Boston, MA	The Impact of Federal Employees' Health Benefits Program Parity on use and Cost Of Mental Health and Substance Abuse Services	Presented original research Academy Health Annual Research Meeting
2006 Boston, MA	The Effect of Incentive Formularies on Medication Continuation and Spending among Elderly Retirees	Invited presenter Harvard Medical School, Department of Ambulatory Care and Prevention
2006 Boston, MA	Utilization Patterns and Costs for One Large Hospice: Lessons for Medicare per Diem Payment System?	Invited presenter Harvard University, Robert Wood Johnson Foundation Scholars Program
2006 Bethesda, MD	Manufacturer Promotional Strategies for SSRIs	Presented original research National Institute of Mental Health Biennial Conference on

		the Economics of Mental Health
2006 Boston, MA	Square Peg, Round Hole? Medicare Part D and Nursing Homes	Invited presenter Beth Israel Deaconess Medical Center, Gerontology Division Ground Rounds
2006 Boston, MA	The Impact of the Federal Employees' Health Benefits Program Mental Health Parity Policy on Use and Costs	Presented original research American Public Health Association Annual Meeting
2007 Washington, DC	Medicare Part D and Pharmacy Services to Residents of Nursing Homes," (joint with David Stevenson, Ph.D.)	Invited presenter Medicare Payment Advisory Commission
2007 Boston, MA	Hospice Decision Making by Advanced Lung Cancer Patients	Invited presenter Dana Farber Cancer Outcomes Research Seminar
2008 Boston, MA	Hospice Care Delivery and Costs: Is There a Better Way?	Invited presenter Boston Bar Association
2008 Washington, DC	Who Uses New Product Formulations of Psychiatric Medications?	Presented original research AcademyHealth Annual Research Meeting
2008 Boston, MA	Discussions about Hospice among Patients with Advanced Lung Cancer	Invited presenter National Cancer Institute Cancer Consortium Meeting
2008 Durham, NC	Who Uses New Product Formulations of Psychiatric Medications?	Presented original research American Society for Health Economists Biennial Conference
2008 Bethesda, MD	New Product Formulations of Antidepressants: What is the Social Value?	Presented original research National Institute of Mental Health Biennial Conference on the Economics of Mental Health

2008 New Haven, CT	New Product Formulations of Antidepressants: What is the Social Value?	Invited presenter Yale University School of Public Health
2009 Lausanne, Switzerland	Antidepressant Reformulations: Who Uses Them and What Are the Benefits?	Invited presenter University of Lausanne
2009 Chicago, IL	Discussions with Physicians about Hospice among Patients with Metastatic Lung Cancer	Presented original research AcademyHealth Annual Research Meeting
2009 Chapel Hill, NC	The Impact of Mental Health and Substance Abuse Parity: Are the Effects the Same for High and Low Spenders?	Invited presenter University of North Carolina, Chapel Hill School of Public Health
2010 Washington, DC	A New Medicare End of Life Benefit for Nursing Home Residents	Invited presenter <i>Health Affairs</i> press briefing
2010 Ithaca, NY	Physician Adoption of New Antipsychotic Medications	Presented original research American Society for Health Economists Biennial Conference
2010 Boston, MA	Physician Adoption of New Psychiatric Medications	Presented original research AcademyHealth Annual Research Meeting
2010 Boston, MA	Health Care Reform and Mental Health	Roundtable presenter AcademyHealth Annual Research Meeting
2010 Boston, MA	Medicare Part D and the Nursing Home Setting	Presented original research AcademyHealth Annual Research Meeting
2011 Ann Arbor, MI	Physician Adoption of New Psychiatric Medications	Invited presenter University of Michigan Department of Psychiatry Grand Rounds
2011 Philadelphia, PA	A New Medicare End of Life Benefit for Nursing Home Residents	Invited presenter National Palliative Care Summit



2011 Toronto, Canada	Part D Plan Generosity and Medication Use among Dually-eligible Nursing Home Residents	Presented original research International Health Economics Association 8 <sup>th</sup> World Congress
2012 Orlando, FL	Physician Adoption and Use of Antipsychotic Medications	Presented original research AcademyHealth Annual Research Meeting
2012 Boston, MA	Physician Prescribing Practices in the 21 <sup>st</sup> Century: A Case Study of Antipsychotics	Presented original research MGH Mongon Institute for Health Policy
2012 Boston, MA	Physician Prescribing Practices in the 21 <sup>st</sup> Century: A Case Study of Antipsychotics	Presented original research HMS Department of Population Medicine
2012 Boston, MA	Physician Prescribing Practices in the 21 <sup>st</sup> Century: A Case Study of Antipsychotics	Presented original research MGH Center for Child and Adolescent
2013 Baltimore, MD	Medicare Part D Plan Generosity and Medication Use among Dual Eligible Nursing Home Residents	Invited presenter AcademyHealth Annual Research Meeting
2013 Portland, OR	Substance Use Disorder Treatment under New Payment and Delivery Models	Presented original research Addiction Health Services Research Annual Meeting
2013 Boston, MA	Impact of Medicare Part D Coverage Restrictions on Nursing Home Resident Outcomes	Presented original research American Public Health Association Annual Meeting
2013 Boston, MA	Mental Health and Substance Use Disorder Treatment under New Payment and Delivery Models	Presented original research Massachusetts General Hospital Grand Rounds
2014 Boston, MA	Mental Health and Substance Use Disorder Treatment under New Payment and Delivery Models	Presented original research Dartmouth College
2014	Effects of a Global Payment and Accountable	Presented original research

Providence, RI	Care Model on Mental Health Service Use and Spending	Brown University
2014 Los Angeles, CA	Effects of a Global Payment and Accountable Care Model on Substance Use Disorder Service Use and Spending	Presented original research American Society for Health Economists Biennial Conference
2014 San Diego, CA	Innovations in Hospice, Palliative Care, and Advanced Illness	Invited presenter AcademyHealth Annual Research Meeting
2014 Boston, MA	Effects of a Global Payment and Accountable Care Model on Substance Use Disorder Service Use and Spending	Presented original research Addiction Health Services Research Annual Meeting
2015 Venice, Italy	Physician Prescribing of Antipsychotics to Children and Adolescents	Presented original research Twelfth Workshop on Costs and Assessment for Psychiatry
2015 Boston, MA	Living the Best Life Possible: Doctor and Patient Conversations about Serious Illness and Mortality	Invited presenter The Forum: T.H. Chan School for Public Health
2015 Marina del Rey, CA	Effects of a Global Payment and Accountable Care Model on Tobacco Cessation Treatment Use and Spending	Presented original research Addiction Health Services Research Annual Meeting
2015 Miami, FL	Effects of a Global Payment and Accountable Care Model on Substance Use Disorder Service Use and Spending	Presented original research APPAM Annual Fall Research Conference
2016 Boston, MA	Opportunities and Challenges for Behavioral Health Care after Parity and the ACA	Keynote Speaker AcademyHealth Behavioral Health Services Research Interest Group Meeting
2017 Chicago, IL	Use of Medications for Opioid Use Disorder Among Commercially Insured Individuals,	Presented original research APPAM Annual Fall Research
2018 Rockville, MD	Predictors of Antipsychotic Drug Diffusion among U.S. Practices Treating Medicare Beneficiaries, 2008-2016	Presented original research NIMH Mental Health Services Research Conference

2018 Savannah, GA	Accountable Care Organization Participation Among Hospitals Offering Substance Use Disorder and Mental Health Services in 2016	Presented original research Addiction Health Services Research Conference
2018 Savannah, GA	How Is Telemedicine Being Used for Opioid and Other Substance Use Disorders?	Presented original research Addiction Health Services Research Conference
2018 Durham, NC	How is Telemedicine Being Used in Opioid and Other Substance Use Disorder Treatment?	Presented original research Duke University School of Medicine, Department of Population Sciences Seminar
2018 Atlanta, GA	How is Telemedicine Being Used in Opioid and Other Substance Use Disorder Treatment?	Presented original research Emory University School of Public Health Health Economics/ Health Policy Seminar
2018 Washington, DC	Research Update on End-of-Life Care Utilization and Spending	Presented original research National Academies of Science, Engineering and Medicine Roundtable on Quality of Care for People with Serious Illness
2019 Venice, Italy	How is Telemedicine Being Used in Opioid and Other Substance Use Disorder Treatment?	Presented original research Fourteenth Workshop on Costs and Assessment in Psychiatry
2019 Barcelona, Spain	How is Telemedicine Being Used in Opioid and Other Substance Use Disorder Treatment?	Presented original research APPAM International Research Conference
2019 Park City, UT	Medication Utilization for Alcohol Use Disorder in a Commercially-Insured Population	Presented original research Addiction Health Services Research Conference
2019 Cambridge, MA	Medication Utilization for Alcohol Use Disorder in a Commercially-Insured Population	Presented original research Mathematica Policy Research Seminar Series
2020 Providence, RI	Telemedicine Use for Substance Use Disorder Treatment before and during COVID-19	Presented original research Brown University School of

Public Health

2020 Virtual	Telemedicine in the Era of COVID-19	Presented original research NIDA Special Interest Group on Telemedicine Seminar (joint with Ateev Mehrotra)
2021 Virtual	Telehealth in Behavioral Health Care: Observations from Before and During the Pandemic	Presented original research Brandeis Harvard NIDA Center Symposium
2021 Virtual	Key MOUD-related Coverage Provisions of Recent Federal Legislation: Private Coverage	Invited presentation NIDA Meeting on Research Needed to Advance the Impact of Medications for Opioid Use Disorder
2021 Virtual	Telehealth for Alcohol Use Disorder (AUD) Treatment: Observations from Before and During the Pandemic	Presented original research Friends of NIAAA
2022 Virtual	Clinical Perspectives for Transitioning SUD Treatment to Virtual Care Environment	Invited presentation National Academies of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic Meeting on Telehealth & Virtual Care

**Report of Education of Patients and Service to the Community**

1996	Advisor	State of Arizona, Office of the Auditor General
1996-1997	Member, Development Team for Technical Assistance Publication	U.S. Public Health Service, Substance Abuse and Mental Health Services Administration
1997-1998	Member, Technical Advisory Panel	The Robert Wood Johnson Foundation Home Care Research Initiative
1999-2000	Consultant, Veterans Administration Pharmacy Formulary Analysis Committee	Institute of Medicine

1999-2004	Co-Sponsor, Joint Seminar on Health Economics	Boston University, Harvard University, Massachusetts Institute of Technology
2000-2002	Member, Advocacy Committee	Coalition for Health Services Research
2001-2002	Member, Committee on Care for Children Who Die Their Families	Institute of Medicine and
2002-2009	Associate Member	MacArthur Foundation Network on Mental Health Policy
2002-2003	Chair, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2003-	Member, Advisory Board, Policy Synthesis Project	Robert Wood Johnson Foundation
2005-2006	Member, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2006-2007	Commission Member, Special Commission on Ambulatory Surgical Centers and Magnetic Resonance Imaging	Commonwealth of Massachusetts Senate and House of Representatives, Joint Committee on Health Care Financing
2006-2007	Member, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2008	Member, Expert Panel on Evaluating Plan Management of the Medicare Drug Benefit	Medicare Payment Advisory Commission (MedPAC)
2008	Member, Consultation Team on Mental Health, Guide to Community Preventive Services	Centers for Disease Control and Prevention (CDC)
2008-2009	Chair, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2009-2010	Member, Planning Committee	AcademyHealth Annual Research Meeting

2009-2010	Member, Committee on Accelerating Rare Diseases Research and Orphan Products Development	Institute of Medicine
2010	Co-Chair, 15 <sup>th</sup> Biennial NIMH Mental Health and Economics Conference	National Institute of Mental Health
2011-2014	Member, Technical Expert Panel, CMS Hospice Payment Reform Project	Centers for Medicare & Medicaid Services (CMS)
2014-2015	Member, Committee on Developing Evidence-Based Standards for Psychosocial Interventions for Mental Disorders	Institute of Medicine
2015-2016	Chair, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2016-	Member, Roundtable on Quality Care for People With Serious Illness	National Academies of Science, Engineering, and Medicine
2017	Co-Chair, Financing and Payment Strategies to Support High-Quality Care for People with Serious Illness: A Workshop	National Academies of Science, Engineering, and Medicine
2021	Member, Medicare Advantage Value-based Insurance Design Hospice Network Adequacy Technical Expert Panel	Centers for Medicare and Medicaid Services (CMS)
2021-2022	Co-Chair, Behavioral Health Theme Leader for Annual Research Meeting	AcademyHealth

**Publications:**

1. **H.A. Huskamp** and J.P. Newhouse, “Is Health Spending Slowing Down?” *Health Affairs*, 13(5): 32-38, (1994).
2. R.G. Frank, **H.A. Huskamp**, T.G. McGuire and J.P. Newhouse, “Some Economics of Mental Health Carveouts,” *Archives of General Psychiatry*, 53: 933-937, (1996).
3. R.G. Frank and **H.A. Huskamp**, “Shaping National Policy: Delegation and Decentralization of Mental Health Care,” *Current Opinion in Psychiatry*, 9: 171-174, (1996).

4. **H.A. Huskamp**, V. Azzone and R.G. Frank, "Carve-outs, Women, and the Treatment of Depression," *Women's Health Issues*, 8(5): 267-282, (1998).
5. **H.A. Huskamp**, "How A Managed Behavioral Health Care Carve-Out and Benefit Expansion Affected Spending on Treatment Episodes," *Psychiatric Services*, 49(11): 1559-1562, (1998).
6. M.B. Rosenthal, R.D. Geraty, R.G. Frank and **H.A. Huskamp**, "Psychiatric Provider Practice Management Companies: Adding Value to Behavioral Health Care?" *Psychiatric Services*, 50(8): 1011-1013, (1999).
7. **H.A. Huskamp** and J.P. Newhouse, "Future Directions for the National Health Accounts," *Health Care Financing Review*, 21(2): 5-13, (1999).
8. **H.A. Huskamp**, "Episodes of Mental Health and Substance Abuse Treatment under a Managed Behavioral Health Care Carve-out," *Inquiry*, 36(2): 147-161, (1999).
9. **H.A. Huskamp**, M.B. Rosenthal, R.G. Frank and J.P. Newhouse, "The Medicare Prescription Drug Benefit: How Will the Game Be Played?" *Health Affairs*, 19(2): 8-23, (2000).
10. K.W. Hanson, **H.A. Huskamp**, "State Health Care Reform: Behavioral Health Services Under Medicaid Managed Care: The Uncertain Implications of State Variation," *Psychiatric Services*, 52(4): 447-456, (2001).
11. **H.A. Huskamp**, D.W. Garnick, K.W. Hanson and C. Horgan, "The Impact of Medicaid Managed Care Plan Withdrawals on Behavioral Health Services," *Psychiatric Services*, 52(5): 600-604, (2001).
12. **H.A. Huskamp**, M.B. Buntin, V. Wang and J.P. Newhouse, "Providing Care at the End of Life: Do Medicare Rules Impede Good Care?" *Health Affairs*, 20(3): 204-211, (2001).
13. M.B. Rosenthal, B.E. Landon and **H.A. Huskamp**, "Managed Care and Market Power: Physician Organizations in Four Markets," *Health Affairs*, 20(5): 187-193, (2001).
14. B.E. Landon, **H.A. Huskamp**, C. Tobias and A.M. Epstein, "The Evolution of Quality Management by State Medicaid Agencies: A National Survey of States with Comprehensive Managed Care Programs," *Joint Commission Journal on Quality Improvement*, 28(2): 72-82, (2002).
15. The Harvard Managed Care Industry Center Group (H. Bailit, D. Blumenthal, J. Buchanan, M. Beeuwkes Buntin, D. Caudry, P. Cleary, A. Epstein, P. Fitzgerald, R. Frank, H. Gorski, **H. Huskamp**, N. Keating, B. Landon, B. McNeil, J. Newhouse, M. Rosenthal, A. Zaslavsky). "Managed Care: An Industry Snapshot," *Inquiry* 39(3): 207-220, (2002).
16. M.B. Buntin and **H.A. Huskamp**, "What is Known About the Economics of End-of-Life Care for Medicare Beneficiaries?" *The Gerontologist*, Vol. 42, Special Issue III, 40-8, (2002).

17. **H.A. Huskamp**, A.M. Epstein and D. Blumenthal, “The Impact of a National Prescription Drug Formulary on Prices, Market Share, and Spending: Lessons for Medicare?” *Health Affairs*, 22(3): 149-158, (2003).
18. R.G. Frank, **H.A. Huskamp** and H.A. Pincus, “Aligning Incentives in the Treatment of Depression in Primary Care with Evidence-based Practice,” *Psychiatric Services*, 54(5): 682-687, (2003).
19. **H.A. Huskamp**, “Managing Psychotropic Drug Costs: Will Formularies Work?” *Health Affairs*, 22(5): 8496, (2003).
20. **H.A. Huskamp**, P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan and R.G. Frank, “The Effect of Incentive-based Formularies on Prescription-Drug Utilization and Spending,” *New England Journal of Medicine*, 349(23): 2224-2232, (2003).
21. S.F. Greenfield, V. Azzone, **H.A. Huskamp**, B. Cuffel, T. Croghan, W. Goldman, and R.G. Frank, “Treatment for Substance Use Disorders in a Privately Insured Population under Managed Care: Costs and Services Use,” *Journal of Substance Abuse Treatment*, 27(4): 265-275, (2004).
22. **H.A. Huskamp**, P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan, A.C. Muriel, and R.G. Frank, “The Impact of Three-Tier Formularies on Treatment of Attention-Deficit/Hyperactivity Disorder in Children,” *Archives of General Psychiatry* 62(4): 435-441, (2005) .
23. **H.A. Huskamp** and N.L. Keating, “The New Medicare Drug Benefit: Formularies and Their Potential Effects on Access to Medications,” *Journal of General Internal Medicine* 20(7):662-665, (2005). PMID: PMC1403290
24. M.E. Domino and **H.A. Huskamp**, “Does Provider Variation Matter to Health Plans?” *Journal of Health Economics* 24(4): 795-813, (2005).
25. **H.A. Huskamp**, R.G. Frank, K.A. McGuigan and Y. Zhang, “The Impact of a Three-Tier Formulary on Demand Response for Prescription Drugs,” *Journal of Economics and Management Strategy* 14(3): 729753, (2005).
26. **H.A. Huskamp**, “Pharmaceutical Cost Management and Access to Psychotropic Drugs: The U.S. Context,” *International Journal of Law and Psychiatry* 28(5):484-495, (2005). PMID:PMC1378114
27. **H.A. Huskamp** and J.A. Shinogle, “Economic Grand Rounds: Potential Effects of the New Medicare Drug Benefit on Pricing for Psychotropic Medications?” *Psychiatric Services* 56(9):1056-1058, (2005). PMID:PMC1403293
28. N.L. Keating, M. Norredam, M.B. Landrum, **H.A. Huskamp**, and E.R. Meara, “Physical and Mental Health Status of Older Long-Term Cancer Survivors,” *Journal of the American Geriatrics Society* 53:2145-2152, (2005).



29. W.F. Gellad, **H.A. Huskamp**, K.A. Phillips, and J.S. Haas, "How the New Medicare Drug Benefit Could Affect Vulnerable Populations", *Health Affairs* 25(1): 248-245, (2006). PMID: PMC1403812
30. H.H. Goldman, R.G. Frank, M.A. Burnam, **H.A. Huskamp**, et al., "Behavioral Health Insurance Parity for Federal Employees," *New England Journal of Medicine* 354(13):1378-1386, (2006).
31. A.B. Busch, **H.A. Huskamp**, S.T. Normand, A.S. Young, H. Goldman, and R.G. Frank, "The Impact of Parity on Major Depression Treatment Quality in the Federal Employees' Health Benefits Program After Parity Implementation," *Medical Care* 44(6): 506-512, (2006). PMID: PMC2587323
32. **H.A. Huskamp**, "Prices, Profits and Innovation: Examining Criticisms of the Value of New Psychotropic Drugs' Value," *Health Affairs* 25(3):635-646, (2006). PMID: PMC2430611
33. D.C. Grabowski, D.G. Stevenson, **H.A. Huskamp**, and N.L. Keating, "The Influence of Medicare Home Health Payment Incentives: Does Payer Source Matter?" *Inquiry* 43(2):135-149, (2006).
34. **H.A. Huskamp**, A.D. Sinaiko, and J.P. Newhouse, "Future Directions for the National Health Expenditure Accounts: Conference Overview," *Health Care Financing Review* 28(1):1-8, (2006).
35. S.T. Azrin, **H.A. Huskamp**, V. Azzone, H.H. Goldman, et al., "Impact of Full Mental Health and Substance Abuse Parity for Children in the Federal Employees Health Benefits Program," *Pediatrics* 119: 452-459, (2007). Available at [www.pediatrics.org](http://www.pediatrics.org). PMID: PMC1995034
36. **H.A. Huskamp**, D.G. Stevenson, J.M. Donohue, J.P. Newhouse, and N.L. Keating, "Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D," *Psychiatric Services* 58(3):308-310, (2007).
37. **H.A. Huskamp**, P.A. Deverka, M.B. Landrum, R.S. Epstein and K.A. McGuigan, "The Effect of Three-Tier Formulary Adoption on Medication Continuation and Spending Among Elderly Retirees," *Health Services Research* 42(5):1926-1942, (2007). PMID: PMC2254563
38. D.G. Stevenson, **H.A. Huskamp**, N.L. Keating, and J.P. Newhouse, "Medicare Part D and Nursing Home Residents," *Journal of the American Geriatrics Society* 55(7): 1115-1124, (2007).
39. A.B. Busch, M.B. Landrum and **H.A. Huskamp**, "Quality of Care for Bipolar-I Disorder in a Medicaid Population with Bipolar I Disorder" *Psychiatric Services* 58(6):848-854, (2007).
40. M.B. Rosenthal, M.B. Landrum, **H.A. Huskamp**, E. Meara, R.M. Conti, and N.L. Keating, "Using Performance Data to Identify Preferred Hospitals," *Health Services Research* 42(6):2109-2119, (2007). PMID: PMC2151404
41. W.F. Gellad, **H.A. Huskamp**, K.A. Phillips, and J.S. Haas, "Angiotensin Receptor Blockers on the Formularies of Medicare Drug Plans," *Journal of General Internal Medicine* 22(8):1172-1175, (2007). PMID: PMC2305745

42. D.G. Stevenson, **H.A. Huskamp**, D.C. Grabowski, and N.L. Keating, “Differences in Hospice Care between Home and Institutional Settings,” *Journal of Palliative Medicine* 10(5):1040-1047 (2007).
43. M.O. Edelen, M.A. Burnam, K. Watkins, J. Escarce, H. Goldman, **H. Huskamp**, and G. Rachelevsky, “Obtaining Utility Estimates of the Health Value of Commonly-Prescribed Treatments for Asthma and Depression,” *Medical Decision Making* 28 (5): 732-750, (2008).
44. D.G. Stevenson, **H.A. Huskamp**, and J.P. Newhouse, “Medicare Part D and the Nursing Home Setting,” *The Gerontologist* 48(4):432-441, (2008). PMID: PMC2538577
45. **H.A. Huskamp**, J.P. Newhouse, J.C. Norcini, and N.L. Keating, “Variation in Patients’ Hospice Costs,” *Inquiry* 45(2): 232-244, (2008).
46. **H.A. Huskamp**, D.G. Stevenson, N.L. Keating, and J.P. Newhouse, “Rejections of Drug Claims for Nursing Home Residents under Medicare Care Part D,” *Health Affairs* 27(2): 560-567, (2008). PMID: PMC2714733
47. **H.A. Huskamp**, J.M. Donohue, C. Koss, E.R. Berndt, and R.G. Frank, “Generic Entry, Reformulations and Promotion of SSRIs in the U.S.,” *Pharmacoeconomics* 26(7):603-616, (2008). PMID:PMC2719790
48. J.M. Donohue, M. Fischer, **H.A. Huskamp**, and J. Weissman, “Potential Savings from an Evidence-Based, Consumer-Oriented Public Education Campaign on Prescription Drugs,” *Health Services Research* 43(5):1557-1575, (2008). PMID: PMC2653882.
49. L.L. Eselius, P.D. Clearly, A.M. Zaslavsky, **H.A. Huskamp**, and S.H. Busch, “Case-Mix Adjustment of Consumer Reports about Managed Behavioral Health Care and Health Plans,” *Health Services Research* 43(6):2014-2032, (2008). PMID: PMC2613989.
50. D.C. Grabowski, **H.A. Huskamp**, D.G. Stevenson, and N.L. Keating, “Ownership Status and Home Health Care Performance,” *Journal of Aging & Social Policy* 21(2):130-143, (2009). PMID: PMC2743947.
51. B. Zhang, A.A. Wright, **H.A. Huskamp**, M.E. Nilsson, M.L. Maciejewski, C.C. Earle, S.D. Block, P.K. Maciejewski, and H.G. Prigerson, “Health Care Costs in the Last Week of Life: Associations with End-of-Life Conversations,” *Archives of Internal Medicine* 169(5):480-488, (2009). PMID: PMC2862687
52. **H.A. Huskamp**, A.B. Busch, M.E. Domino, and S-L Normand, “Antidepressants Reformulations: Who Uses Them, and What Are The Benefits?” *Health Affairs* 28(3):734-745, (2009). PMID: PMC2752284
53. J.M. Donohue, **H.A. Huskamp**, and S.H. Zuvekas, “Dual-eligibles with Mental Disorders and Part D: How Are They Faring?” *Health Affairs* 28(3):746-759, (2009). PMID: PMC2773509
54. K.E. Watkins, M.A. Burnam, M. Orlando, J. Escarce, **H.A. Huskamp**, and H.H. Goldman, “The Health Value and Cost of Care for Major Depression,” *Value in Health* 12(1):65-72, (2009).

55. J.M. Donohue, **H.A. Huskamp**, I.B. Wilson, and J. Weissman, "Whom Do Older Adults Trust Most to Provide Information about Prescription Drugs?" *American Journal of Geriatric Pharmacotherapy* 7(2):105116, (2009). PMID: PMC2782479
56. **H.A. Huskamp**, N.L. Keating, J.L. Malin, A.M. Zaslavsky, J.C. Weeks, C.C. Earle, J.M. Teno, B.A. Virnig, K.L. Kahn, Y. He, and J.Z. Ayanian, "Discussions with Physicians about Hospice among Patients with Metastatic Lung Cancer," *Archives of Internal Medicine* 169(10):954-962, (2009). PMID: PMC2689617
57. **H.A. Huskamp**, J.C. West, D.S. Rae, M. Rubio-Stipec, D.A. Regier, and R.G. Frank, "Part D and Dual Eligibles with Mental Illness: Problems Accessing Medications and Implications for Use of Intensive Mental Health Services," *Psychiatric Services* 60(9):1169-1174, (2009). PMID: PMC2768558
58. **H.A. Huskamp** and M.B. Rosenthal, "Health Risk Appraisals: How Much Do They Influence Employees' Health Behavior?" *Health Affairs* 28(5):1532-1540, (2009).
59. C.L. Barry, H.H. Goldman, R.G. Frank, and **H.A. Huskamp**, "Lessons for Health Reform from the Hard-won Success of Behavioral Health Insurance Parity," *American Journal of Psychiatry* 166(9):969-971, (2009). PMID: PMC2739113
60. A.B. Busch, **H.A. Huskamp**, B. Neelon, T. Manning, S.T. Normand, and T.G. McGuire, "Longitudinal Racial/Ethnic Disparities in Antimanic Medication Prescribing for Bipolar-I Disorder," *Medical Care* 47(12):1217-1228, (2009). PMID: PMC2787883
61. M. Norredam, E. Meara, M.B. Landrum, **H.A. Huskamp**, and N.L. Keating, "Financial Status, Employment and Insurance among Older Cancer Survivors," *Journal of General Internal Medicine* 24 Suppl 2:S438-445, (2009). PMID: PMC2763157
62. N.L. Keating, M.B. Landrum, S.O. Rogers, S.K. Baum, B.A. Virnig, **H.A. Huskamp**, C. C. Earle, and K.L. Kahn, "Physician Factors Associated with Discussions about End-of-Life Care," *Cancer* 116(4):998-1006, (2010). PMID: PMC2819541
63. **H.A. Huskamp**, D.G. Stevenson, M.E. Chernew, and J.P. Newhouse, "A New Medicare End-of-Life Benefit for Nursing Home Residents" *Health Affairs* 29(1):130-135, (2010).
64. K.B. Gibler, **H.A. Huskamp**, M.S. Sabatine, S.A. Murphy, D.J. Cohen, and C.P. Cannon, "Cost-Effectiveness Analysis of Short-Term Clopidogrel Therapy for ST Elevation Myocardial Infarction," *Critical Pathways in Cardiology* 9(1):14-18, (2010).
65. D.G. Stevenson, S.L. Decker, L.L. Dwyer, **H.A. Huskamp**, D.C. Grabowski, E.D. Metzger, and S.L. Mitchell, "Antipsychotic and Benzodiazepine Use among Nursing Home Residents: findings from the 2004 National Nursing Home Survey," *American Journal of Geriatric Psychiatry* 18(12):1078-92, (2010). PMID: PMC3009456

66. **H.A. Huskamp**, D.G. Stevenson, D.C. Grabowski, E. Brennan, and N.L. Keating, “Long and Short Hospice Stays among Nursing Home Residents at the End of Life,” *Journal of Palliative Medicine* 13(8):957-64, (2010).
67. C.L. Barry, **H.A. Huskamp**, and H.H. Goldman, “A Political History of Federal Mental Health and Addiction Insurance Parity,” *Milbank Quarterly* 88(3):404-433, (2010). PMID: PMC2950754
68. J.C. West, **H.A. Huskamp**, D.S. Rae, M. Rubio-Stipec, D.A. Regier, “Medicaid Medication Access Problems and Increased Psychiatric Hospital and Emergency Care,” *General Hospital Psychiatry* 32(6):615622, (2010).
69. J. Zhu, P. Zawarsky, S. Lipsitz, **H.A. Huskamp**, and J.S. Haas, “Massachusetts Health Reform and Disparities in Coverage, Access, and Health Status,” *Journal of General Internal Medicine* 25(12):1356-62, (2010). PMID: PMC2988151
70. K. Backes Kozhimannil, **H.A. Huskamp**, A.J. Graves, S.B. Soumerai, D. Ross-Degnan, and J.F. Wharam, “High-Deductible Health Plans and Cost and Utilization of Maternity Care,” *American Journal of Managed Care* 17(1):e17-25, (2011).
71. K. Backes Kozhimannil, A.S. Adams, S.B. Soumerai, A.B. Busch, and **H.A. Huskamp**, “New Jersey’s Efforts to Improve Postpartum Depression Care Did Not Change Treatment Patterns for Women on Medicaid,” *Health Affairs* 39(2):293-301, (2011).
72. M.Y. Martin, M. Pisu, R.A. Oster, J.G. Urmie, D. Schrag, **H.A. Huskamp**, J. Lee, C.I. Kiefe, and M. Fouad, “Racial Variation in Willingness to Trade Financial Resources for Life Prolonging Cancer Treatment,” *Cancer* 2011 Aug 1;117(15):3476-84, (2011), PMID: PMC3142305
73. K. Backes Kozhimannil, C.M. Trinacty, A.B. Busch, **H.A. Huskamp**, and A.S. Adams, “Racial and ethnic Disparities in Postpartum Depression Care among Low-income Women,” *Psychiatric Services* 62:619-625, (2011).
74. F.B. Yoon, **H. A. Huskamp**, Alisa B. Busch, and Sharon-Lise T. Normand, “Using Multiple Control Groups and Matching to Address Unobserved Biases in Comparative Effectiveness Research,” *Statistics in Biosciences* 3(1):63-78, (2011). PMID:PMC3182124
75. J.M. McWilliams, A.M. Zaslavsky, and **H.A. Huskamp**, “Implementation of Medicare Part D and Non-drug Medical Spending for Elderly Adults with Limited Prior Drug Coverage,” *JAMA* 306(4):402-409, (2011).
76. C.L.Barry and **H.A. Huskamp**, “Moving beyond Parity – Mental Health and Addiction Care under the ACA,” *NEJM* 365 (11):973-975, (2011). PMID: PMC3359059

77. J.M. Polinski, W.H. Shrank, **H.A. Huskamp**, R.J. Glynn, J.N. Liberman, et al. “Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap,” *PLoS Med* 8(8): e1001075.doi:10.1371/journal.pmed.1001075, (2011). PMID: PMC3156689
78. W.F. Gellad, **H.A. Huskamp**, A. Li, Y. Zhang, D.G. Safran, and J.M. Donohue, “Use of Prescription Drug Samples and Patient Assistance Programs, and the Role of Doctor-Patient Communication,” *Journal of General Internal Medicine* 26(12):1458-64, (2011). PMID: PMC3235606.
79. **H. A. Huskamp**, C. Kaufman, and D.G. Stevenson, “The Intersection of Long-term Care and End-of-Life Care,” *Medical Care Research and Review* 69(1):3-44, (2012).
80. J.W. Mack, A. Cronin, N. Taback, **H.A. Huskamp**, N.L. Keating, J.L. Malin, C.C. Earle, and J.C. Weeks, “End-of-life Care Discussions among Patients with Advanced Cancer: A Cohort Study,” *Annals of Internal Medicine* 156(3): 204-210, (2012).
81. S.B. Dusetzina, A.S. Higashi, E.R. Dorsey, R. Conti, **H.A. Huskamp**, S. Zhu, C.F. Garfield, and G.C. Alexander, “Impact of FDA Risk Communications on Health Care Utilization and Health Behaviors: A Systemic Review,” *Medical Care*, 50(6): 466-78, (June, 2012). PMID: PMC3342472
82. H.H. Goldman, C.L. Barry, S. T. Normand, V. Azzone, A.B. Busch, and **H.A. Huskamp**, “Economic Grand Rounds: The Price is Right? Changes in Quantity of Services Used and Prices Paid in Response to Parity,” *Psychiatric Services* 63(2):107-109, (2012). PMID: PMC22302324.
83. C.F. Garfield, E.R.Dorsey, S. Zhu, **H.A. Huskamp**, R.Conti, S.B. Dusetzina, A. Higashi, J.M. Perrin, R. Kornfield, and G.C. Alexander, “Trends in Attention Deficit Hyperactivity Disorder (ADHD) Ambulatory Diagnosis and medical Treatment in the United States, 2000-2010,” *Academic Pediatrics*: 12 (2): 110-6, (2012). PMID: PMC3307907
84. J. Glazer, **H.A. Huskamp**, and T.G. McGuire, “A Prescription for Drug Formulary Evaluation: an Application of Price Indexes,” *Forum for Health Economics and Policy* 15 (2), March 2012 [epub ahead of print].
85. J.M. Polinski, W.H. Shrank, R.J. Glynn, **H.A. Huskamp**, M.C. Roebuck, and S. Schneeweiss, “Beneficiaries with Cardiovascular Disease and the Part D Coverage Gap,” *Circulation: Cardiovascular Quality and Outcomes*, 5(3): 387-95, (May 2012). PMID: PMC3361758
86. M.E. Burns, B.J. O’Hara, **H.A. Huskamp**, and S.B. Soumerai, “Uninsurance and Its Correlates among Poor Adults with Disabilities,” *Journal of Health Care for the Poor and Underserved* 23(4):1630-46, (2012).
87. S.B. Dusetzina, A.B. Busch, R.M. Conti, J.M. Donohue, G.C. Alexander, and **H.A. Huskamp**, “Changes in Antipsychotic Use among Patients with Severe Mental Illness after an FDA Advisory,” *Pharmacoepidemiology and Drug Safety* 21(12): 1251-60, (2012).

88. J.M. Polinski, W.H. Shrank, R.J. Glynn, **H.A. Huskamp**, M.C. Roebuck, and S. Schneeweiss, "Association between the Part D Coverage Gap and Adverse Health Outcomes, *Journal of the American Geriatric Society* 60(8): 1408-17, (2012).
89. D.G. Stevenson, L. Keohane, S.L. Mitchell, B.J. Zarowitz, and **H.A. Huskamp**, "Medicare Part D Claims Rejections for Nursing Home Residents, 2006-2010," *American Journal of Managed Care* 18(10): 647-54, (2012). PMC3540110
90. M.J. Chace, F. Zhang, C.A. Fullerton, **H.A. Huskamp**, D. Gilden, and S.B. Soumerai, "Intended and Unintended Consequences of the Gabapentin Off-label Marketing Lawsuit among Patients with Bipolar Disorder," *Journal of Clinical Psychiatry* 73(11): 1388-94, (2012).
91. M.R. McKellar, M. Frank, **H.A. Huskamp**, and M.E. Chernew, "The Value of Patent Expiration," *Forum for Health Economics and Policy* 15(2): pii: 1558-9544, (2012).
92. J.W. Mack, A. Cronin, N.L. Keating, N. Taback, **H.A. Huskamp**, J.L. Malin, C.C. Earle, and J.C. Weeks, "Associations between End-of-life Discussion Characteristics and Care Received near Death: A Prospective Cohort Study," *Journal of Clinical Oncology* 30(35):4387-95, (2012).
93. S.B. Dusetzina, B. Cook, A.B. Busch, G.C. Alexander, and **H.A. Huskamp**, "Racial-Ethnic Differences in Incentives Olanzapine Use after An FDA Advisory for Patients with Schizophrenia," *Psychiatric Services* 64(1): 83-7, (2013).
94. **H.A. Huskamp**, A.J. O'Malley, M. Horvitz-Lennon, A.L. Taub, E.R. Berndt, and J.M. Donohue, "How Quickly Do Physicians Adopt New Drugs? The Case of Second Generation Antipsychotics," *Psychiatric Services* 64(4):324-30, (2013). PMID: 544941
95. A.B. Busch, F. Yoon, C.L. Barry, V. Azzone, S.-L.-T. Normand, H.H. Goldman, and **H.A. Huskamp**, "The Effects of Mental Health Parity on Spending and Utilization for Bipolar, Major Depression, and Adjustment Disorders," *American Journal of Psychiatry* 170(2): 180-187, (2013). PMID: 492486
96. R. Kornfield, S. Watson, A.S. Higashi, R.M. Conti, S.B. Dusetzina, C.F. Garfield, E.R. Dorsey, **H.A. Huskamp**, and G.C. Alexander, "Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004-2008," *Psychiatric Services* 64(4):339-46, (2013)
97. S.B. Dusetzina, G.C. Alexander, R.A. Freedman, **H.A. Huskamp**, N.L. Keating. "Trends in Co-Prescribing of Antidepressants and Tamoxifen among Women with Breast Cancer, 2004-2010," *Breast Cancer Research and Treatment* 137(1): 285-96, (2013).
98. C. Barry, A. Chien, S. Normand, A. Busch, V. Azzone, H. Goldman, and **H.A. Huskamp**, "Parity and Out-of-Pocket Spending for Children with High Mental Health or Substance Abuse Expenditures," *Pediatrics* 131(3):e903-911, (2013). PMID: 3581843

99. S.H. Busch, E. Meara, **H.A. Huskamp**, and C.L. Barry, "Characteristics of Adults with Substance Use Disorders Expected to be Medicaid Eligible under the Affordable Care Act," *Psychiatric Services* 64(6):520-6, (2013).
100. A. Gallini, **H.A. Huskamp**, and J.M. Donohue, "Diffusion of Antipsychotics in the U.S. and French Markets," *Psychiatric Services* 64(7):680-7, (2013). PMID: [545657](#)
101. R.M. Conti, S.B. Dusetzina, A.C. Herbert, E.R. Berndt, **H.A. Huskamp**, and N.L. Keating, "The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-Administered Drugs: The Case of Bevacizumab for Breast Cancer," *Medical Care* 51:621-627, (2013).
102. **H.A. Huskamp**, D.G. Stevenson, A.J. O'Malley, S.B. Dusetzina, S.L. Mitchell, B.J. Zarowitz, M.E. Chernew, and J.P. Newhouse, "Medicare Part D Plan Generosity and Medication Use among Dual Eligible Nursing Home Residents," *Medical Care* 51(10):894-900, (2013). PMID: [3773176](#)
103. M.E. Burns, A.B. Busch, J. Madden, R. Le Cates, F. Zhang, A. Adams, D. Ross-Degnan, S.B. Soumerai, and **H.A. Huskamp**, "Effects of Medicare Part D on Guideline-concordant Pharmacotherapy for Bipolar I Disorder among Dual Beneficiaries," *Psychiatric Services* 65(3):323-329, (2014).
104. S.B. Dusetzina, A. Winn, G. Abel, **H.A. Huskamp**, and N.L. Keating. Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia, *Journal of Clinical Oncology* 32(4):306-3111, (2014).
105. J.M. Donohue, A.J. O'Malley, M. Horvitz-Lennon, A. Levine Taub, E.R. Berndt, and **H.A. Huskamp**. "Changes in Physician Antipsychotic Prescribing Preferences, 2002-2007," *Psychiatric Services* 65(3):315322, (2014). PMID # [545599](#)
106. P-H Liu, M.B. Landrum, J.C. Weeks, Y. He Y, **H.A. Huskamp**, K.L. Kahn, J.W. Mack, N.L. Keating, "Physicians' Propensity to Discuss Prognosis is Associated with Patient's Awareness of Progress for Metastatic Cancers," *Journal of Palliative Medicine* 17(6):673-82, (2014).
107. D.G. Stevenson and **H.A. Huskamp**, "Integrating Care at the End of Life: Should Medicare Advantage Include Hospice?" *JAMA* 311(15):1493, (2014).
108. J.M. Madden, A.S. Adams, R.F. LeCates, D. Ross-Degnan, F. Zhang, **H.A. Huskamp**, D.M. Gilden, S.B. Soumerai, "Changes in Drug Coverage Generosity and Untreated Serious Mental Illness: Transitioning from Medicaid to Medicare Part D," *JAMA Psychiatry* 72(2): 179-88, (2015).
109. E.A. Stuart, **H.A. Huskamp**, K. Duckworth, J. Simmons, Z., M. Chernew, and C.L. Barry. "Using Propensity Scores in Difference-in-differences Models to Estimate the Effects of a Policy Change," *Health Services & Outcomes Research Methodology* 14(4): 166-82, (2014).
110. D.G. Stevenson, S.B. Dusetzina, A.J. O'Malley, S.L. Mitchell, B.J. Zarowitz, M.E. Chernew, J.P.

Newhouse, and **H.A. Huskamp**, “High-Risk Medication Use by Nursing Home Residents Before and After Hospitalization,” *Medical Care* 52(10):884-90, (2014).

111. D.G. Stevenson, A.J. O’Malley, S.B. Dusetzina, S.L. Mitchell, B.J. Zarowitz, M.E. Chernew, J.P. Newhouse, and **H.A. Huskamp**, “Effect of Part D Coverage Restrictions for Antidepressants, Antipsychotics, and Cholinesterase Inhibitors on Related Nursing Home Resident Outcomes,” *Journal of the American Geriatrics Society* 62(9):1666-74, (2014).
112. **H.A. Huskamp**, N.L. Keating, J.B. Dalton, M.E. Chernew, and J.P. Newhouse, “Drug Plan Design Incentives among Medicare Prescription Drug Plans,” *American Journal of Managed Care* 20(7):562, (2014).
113. D.G. Stevenson, J.B. Dalton, D.C. Grabowski, and **H.A. Huskamp**. “Nearly Half of All Medicare Hospice Enrollees Received Care from Agencies Owned by Regional or National Chains,” *Health Affairs* 34(1):30-8, (2015).
114. T.S. Anderson, **H.A. Huskamp**, A.J. Epstein, C.L. Barry, A. Men, E.R. Berndt, M. Horvitz-Lennon, S-L Normand, J. Donohue, “Antipsychotic Prescribing: Do Conflict of Interest Policies Make a Difference?” *Medical Care* 53(4): 338-45, (2015).
115. **H.A. Huskamp**, “The Affordable Care Act’s Dependent Coverage Provision and Young Adults with Psychiatric Disorders,” *American Journal of Psychiatry* 172(2):113-4, (2015).
116. A.S. Adams, S.B. Soumerai SB, F. Zhang, D. Gilden, M. Burns, **H.A. Huskamp**, C. Trinacty, M. Alegria, R.F. LeCates, J.J. Griggs, D. Ross-Degnan, J.M. Madden, “Effects of Eliminating Drug Caps on Racial Differences in Antidepressant Use Among Dual Enrollees With Diabetes and Depression,” *Clinical Therapeutics* 37(3):597-609, (2015).
117. J.M. Madden, A.S. Adams, R.F. LeCates, D. Ross-Degnan, F. Zhang, **H.A. Huskamp**, D.M. Gilden, and S.B. Soumerai, “Changes in Drug Coverage Generosity and Untreated Serious Mental Illness: Transitioning from Medicaid to Medicare Part D,” *JAMA Psychiatry* 72(2):179-88, (2015).
118. S.B. Dusetzina, S. Ellis, R.A. Freedman, R.M. Conti, A.N. Winn, J.D. Chambers, G.C. Alexander, **H.A. Huskamp**, N.L. Keating. “How do Payers Respond to Regulatory Actions? The Case of Bevacizumab,” *Journal of Oncology Practice* 11(4):313-8, (2015).
119. K.N. Berry, **H.A. Huskamp**, H.H. Goldman, and C.L. Barry, “A Tale of Two States: Do Consumers See Mental Health Insurance Parity When Shopping on State Exchanges,” *Psychiatric Services* 66(6): 565-7, (2015).
120. E.E. McGinty, S.H. Busch, E. Stuart, **H.A. Huskamp**, T. Gibson, H.G. Goldman, and C.L. Barry. “How Does Federal Parity Affect Out-of-network Substance Use Disorder Treatment?” *Health Affairs* 34(8):1331-9, (2015).



121. N.L. Keating, M.B. Landrum, **H.A. Huskamp**, E.M. Kouri, H.G. Prigerson, D. Schrag, P.K. Maciejewski, M.C. Hornbrook, and D.A. Haggstrom, "Dartmouth Atlas Area-level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients?" *Health Services Research* 51(4):1584-94, (2016).
122. S.N. Bandara, **H.A. Huskamp**, L.E. Riedel, E.E. McGinty, D.W. Webster, R.E. Toone, and C.L. Barry. "Leveraging the Affordable Care Act to Enroll Justice-Involved Populations in Medicaid: State and Local Efforts," *Health Affairs* 34(12):2044-51, (2015).
123. C.L. Barry, E.A. Stuart, J.M. Donohue, S.F. Greenfield, E. Kouri, K. Duckworth, Z. Song, R.E. Mechanic, M.E. Chernew, and **H.A. Huskamp**, "The Early Impact of the 'Alternative Quality Contract' on Mental Health Service Use and Spending in Massachusetts," *Health Affairs* 34(12):2077-85, (2015).
124. Y. Tang, C.C. Chang, J.R. Lave, W.F. Gellad, **H.A. Huskamp**, and J.M. Donohue, "Patient, Physician and Organizational Influences on Variation in Prescribing Behavior," *Journal of Mental Health Policy and Economics* 19 (1): 45-59, (2016).
125. W. Lo-Ciganic, W.F. Gellad, **H.A. Huskamp**, N.K. Choudhry, C.H. Chang, R. Zhang, B.L. Jones, H. Guclu, S. Richards-Shubik, and J.M. Donohue, "Who Were the Early Adopters of Dabigatran? An Application of Group-Based Trajectory Models," *Medical Care* 54(7):725-32, (2016).
126. M.E. Burns, **H.A. Huskamp**, J.C. Smith, J.M. Madden, and S.B. Soumerai, "The Effects of the Transition from Medicaid to Medicare on Health Care Use for Adults with Mental Illness," *Medical Care* 54(9):866877, (2016).
127. **H.A. Huskamp**, "Ensuring Health Plans' Compliance with MHPAEA and the ACA," *Psychiatric Services* 67(2): 149, (2016).
128. D.G. Stevenson, D.C. Grabowski, N.L. Keating, and **H.A. Huskamp**, "The Impact of Ownership on Hospice Service Use, 2005-2011," *Journal of American Geriatrics Society* 64(5):1024-31, (2016).
129. **H.A. Huskamp**, M. Horvitz-Lennon, E.R. Berndt, S.-L. T. Normand, and J.M. Donohue, "Patterns of Physician Antipsychotic Prescribing to Young Children," *Psychiatric Services* 67(12):1307-14, (2016).
130. **H.A. Huskamp**, S.F. Greenfield, E.A. Stuart, J.M. Donohue, K. Duckworth, E.M. Kouri, PhD<sup>1</sup>, Z. Song, M.E. Chernew, and C.L. Barry, "Effects of Global Payment and Accountable Care on Tobacco Cessation Service Use: An Observational Study," *Journal of General Internal Medicine* 31(10):1134-40, (2016).
131. J.M. Donohue, S.T. Normand, M. Horvitz-Lennon, A. Men, E.R. Berndt, and **H.A. Huskamp**, "Regional Variation in Physician Adoption of Antipsychotics: Impact on U.S. Medicare Expenditures," *Journal of Mental Health Policy and Economics* 19:69-78, (2016).
132. C.L. Barry, H.H. Goldman, and **H.A. Huskamp**, "Federal Parity in the Evolving Mental Health and Addiction Care Landscape," *Health Affairs* 35(6):1009-1016, (2016).

- 133.L. Hatfield, **H.A. Huskamp**, and E.B. Lamont, “Survival and Toxicity after Cisplatin/etoposide vs Carboplatin/etoposide for Extensive Stage Small Cell Lung Cancer in Elderly Patients,” *Journal of Oncology Practice* 12(7):666-673, (2016).
- 134.L.E. Riedel, C.L. Barry, E.E. McGinty, S.N. Bandara, D.W. Webster, R.E. Toone, and **H.A. Huskamp**, “Improving Health-Care Linkages for Criminal-Justice Involved Persons: The Cook County Jail Medicaid Enrollment Initiative,” *Journal of Correctional Health Care* 22(3):189-99, (2016).
- 135.A. Kennedy-Smith, **H.A. Huskamp**, and C.L. Barry, “Improving Access to Care and Reducing Involvement in the Criminal Justice System for People with Mental Illness,” *Health Affairs*, 35(6):107683, (2016).
- 136.N.L. Keating, M.B. Landrum, **H.A. Huskamp**, Kouri E.M., H.G. Prigerson, D. Schrag, P.K. Maciejewski, M.C. Hornbrook, and D.A. Haggstrom, “Dartmouth Atlas Area-level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Lung Cancer Patients,” *Health Services Research* 51(4):1584-1594, (2016).
- 137.E.A. Stuart, C.L. Barry, J.M. Donohue, S.F. Greenfield, K. Duckworth, Z. Song, E.M. Kouri, C. Ebnesajjad, R. Mechanic, M.E. Chernew, and **H.A. Huskamp**, “Effects of Accountable Care and Payment Reform on Substance Use Disorder Treatment: Evidence from the Initial Three Years of the Alternative Quality Contract,” *Addiction* 112(1):124-33, (2016).
- 138.A.B. Busch, **H.A. Huskamp**, and J.M. McWilliams, “Early Efforts by Medicare Accountable Care Organizations Have Limited Effect on Mental Illness Care and Management,” *Health Affairs* 35(7):12471256, (2016).
- 139.**H.A. Huskamp** and J.K. Iglehart, “Mental Health and Substance-Use Reforms – Milestones Reached, Challenges Ahead,” *New England Journal of Medicine* 375(7):688-695, (2016).
140. E.A. Stuart, E.E. McGinty, L. Kalb, **H.A. Huskamp**, S.H. Busch, T.B. Gibson, H. Goldman, and C.L. Barry, “Increased Service Use Among Children With Autism Spectrum Disorder Associated With Mental Health Parity Law,” *Health Affairs* 36:337-45, (2017).
- 141.J.M. McWilliams, L.G. Gilstrap, D.G. Stevenson, M.E. Chernew, **H.A. Huskamp**, and D.C. Grabowski, “Changes in Postacute Care in the Medicare Shared Savings Program,” *JAMA Internal Medicine* 177(4):518-26, (2017).
- 142.A. Mehrotra, **H.A. Huskamp**, J. Souza, L. Uscher-Pines, S. Rose, B.E. Landon, A.B. Jena, and A.B. Busch, “Rapid Growth in Mental Health Telemedicine Use among Rural Medicare Beneficiaries, Wide Variation across States,” *Health Affairs* 36(5):909-17, (2017).

- 143.S.H. Busch, E.E. McGinty, EA Stuart, **H.A. Huskamp**, TB Gibson, HH Goldman, and CL Barry, “Was Federal Parity Associated with Changes in Out-of-network Mental Health Care Use and Spending?” *BMC Health Service Research* 17(1):315, (2017).
- 144.M.S. Schuler, N.R. Joyce, **H.A. Huskamp**, E.B. Lamont, and L.A. Hatfield, “Medicare Beneficiaries with Advanced Cancer Experience Diverse Patterns of Care from Diagnosis to Death,” *Health Affairs* 36(7):1193-1200, (2017).
- 145.A.B. Busch, **H.A. Huskamp**, A.R. Kreider, and J.M.McWilliams, “Medicare Accountable Care Organizations and Antidepressant Use in Patients with Depression,” *Psychiatric Services* 68(11): 1193-1196, (2017).
- 146.N.R. Joyce, **H. A. Huskamp**, Scott Hadland , J.M. Donohue, S.F. Greenfield, E.A.. Stuart, and C.L. Barry, “The Alternative Quality Contract: Impact on Service Use and Spending for Children with ADHD,” *Psychiatric Services* 68(12): 1210-1212, (2017).
- 147.K.N. Berry, **H.A. Huskamp**, H.H. Goldman, R. Rutkow, and C.L.Barry, “Litigation Provides Clues to Ongoing Challenges in Implementing Insurance Parity,” *Journal of Health Politics, Policy and Law* 42(6):1065-1098, (2017).
- 148.J.W. Koma, J.M. Donohue, C.L. Barry, **H.A. Huskamp**, and M.P. Jarlenski, “Medicaid Coverage Expansions and Cigarette Smoking Cessation among Low-income Adults,” *Medical Care* 55(12): 1023-1029, (2017).
- 149.S.B. Dusetzina, **H.A. Huskamp**, A.N. Winn, E.M. Basch, and N.L. Keating, “Out-of-Pocket and Health Care Spending Changes for Patients Using Orally-Administered Anticancer Therapy After Adoption of State Parity Laws,” *JAMA Oncology* Jun 14;4(6):e173598, (2018).
- 150.J.M. Donohue, C.L., E.A. Stuart, S.F. Greenfield, Z. Song, M.E. Chernew, and **H.A. Huskamp**, “Effects of Global Payment and Accountable Care on Medication Treatment for Alcohol and Opioid Use Disorders,” *Journal of Addiction Medicine* 12(1):11-18, (2018).
- 151.A.C. Fowler, D.C. Grabowski, R.J. Gambrel, **H.A. Huskamp**, and D.G. Stevenson, “Corporate Investors Increased Common Ownership in Hospitals and the Postacute Care and Hospice Sectors,” *Health Affairs* 36:1547-55, (2017).
- 152.N.L. Keating, **H.A. Huskamp**, D. Schrag, J.M. McWilliams, B.J. McNeil, B.E. Landon, M.E. Chernew, and S-L.T. Normand, “Diffusion of Bevacizumab across Oncology Practices: An Observational Study,” *Medical Care* 56(1): 69-77, (2018).
- 153.T.S. Anderson, W. Lo-Ciganic, W.F. Gellad, R. Zhang, **H.A. Huskamp**, N.K. Choudhry, C.H. Chang, S. Richards-Shubik, H. Guclu, B. Jones, and J.M. Donohue, “Patterns and Predictors of Physician Adoption of New Cardiovascular Drugs,” *Healthcare: The Journal of Delivery Science and Innovation*, in press.

154. **H.A. Huskamp**, H. Samples, S.E. Hadland, E.E. McGinty, T.B. Gibson, H.H. Goldman, S.H. Busch, E.A. Stuart, and C.L. Barry, "Mental Health Spending and Intensity of Service Use among Individuals with Diagnoses of Eating Disorders Following Federal Parity Legislation," *Psychiatric Services* 69(2): 217223, (2018).
155. **H.A. Huskamp**, L.E. Riedel, C.L. Barry, and A.B. Busch, "Coverage of Medications that Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017," *Medical Care* 56(6):505509, (2018).
156. J.M. Donohue and **H.A. Huskamp**, "Doughnuts and Discounts – Changes to Medicare Part D under the Bipartisan Budget Act of 2018," *New England Journal of Medicine* 378:1957-1960, (2018).
157. A. Kennedy-Hendricks, A.J. Epstein, E.A. Stuart, R. Haffajee, E.E. McGinty, A.B. Busch, **H.A. Huskamp**, and C.L. Barry, "Federal Parity and Spending for Mental Illness," *Pediatrics*, epub ahead of print, (2018).
158. T.S. Anderson, W. Lo-Ciganic, W.F. Gellad, R. Zhang, **H.A. Huskamp**, N.K. Choudhry, C.H. Chang, S. Richards-Shubik, H. Guclu, B. Jones, and J.M. Donohue, "Patterns and Predictors of Physician Adoption of New Cardiovascular Drugs," *Healthcare* 6: 33-40, (2018).
159. N.L. Keating, **H.A. Huskamp**, E.M. Kouri, D. Schrag, M.C. Hornbrook, D.A. Haggstrom, and M.B. Landrum, "Factors Contributing to Geographic Variation in End-of-life Expenditures for Cancer Patients," *Health Affairs* 37(7):1136-43, (2018).
160. M.J. McDowell, A.B. Busch, A.P. Sen, E.A. Stuart, L. Riedel, C.L. Barry, and **H.A. Huskamp**, "Participation in Accountable Care Organizations among Hospitals Offering Substance Use Disorder and Mental Health Services in 2016," *Psychiatric Services* 69(11):1131-34, (2018).
161. J.M. Donohue, H. Guclu, W.F. Gellad, C.H. Chang, **H.A. Huskamp**, N.K. Choudhry, R. Zhang, W. LoCiganic, S.P. Junker, T. Anderson, and S. Richards-Shubik. "Influence of Peer Networks on Physician Adoption of New Drugs," *PLOS ONE* 13(10): e0204826, (2018).
162. L.G. Gilstrap, **H.A. Huskamp**, D.G. Stevenson, M.E. Chernew, D.C. Grabowski, and J.M. McWilliams, "Changes in End of Life Care in the Medicare Shared Savings Program," *Health Affairs* 37(10):1693-1700, (2018).
163. **H.A. Huskamp**, A.B. Busch, J. Souza, L. Uscher-Pines, S. Rose, A. Wilcock, B.E. Landon, A. Mehrotra, "How is Telemedicine Being Used in Opioid and Other Substance Use Disorder Treatment?" *Health Affairs* 37(12):1940-47, (2018).
164. S. Choi, A.D. Wilcock, A.B. Busch, **H.A. Huskamp**, L. Uscher-Pines, Z. Shi, and A. Mehrotra, "Association of Characteristics of Psychiatrists With Use of Telemental Health Visits in the Medicare Population," *JAMA Psychiatry* 76(6):654-57, (2019).

- 165.S.B. Dusetzina, **H.A. Huskamp**, and N.L. Keating, “Specialty Drug Pricing and Out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Medicare Part D, 2010 to 2018,” *JAMA* 321(20):2025-27, (2019).
- 166.A.D. Wilcock, S. Rose, A.B. Busch, **H.A. Huskamp**, L. Uscher-Pines, B. Landon, and A. Mehrotra, “Association between Broadband Internet Availability and Telemedicine Use,” *JAMA Internal Medicine* 179(11):1580-2, (2019).
- 167.S.B. Dusetzina, N.L. Keating, and **H.A. Huskamp**, “Proposals to Redesign Medicare Part D -- Easing the Burden of Rising Drug Prices,” *NEJM* 381(15):1401-04, (2019).
- 168.I.D Metes, L. Xue, C.H. Chang, **H.A. Huskamp**, W.F. Gellad, W. Lo-Ciganic, N.K. Choudhry, S. Richards-Shubik, H. Glucu, and J.M. Donohue, “Association between Physician Adoption of a New Oral Anti-diabetic Medication and Medicare and Medicaid Drug Spending,” *BMC Health Services Research* 19(1):703, (2019).
- 169.Z. Shi, **H.A. Huskamp**, J. Souza, A.B. Busch, L. Uscher-Pines, and A. Mehrotra, “Characteristics of Organizations that Provide Telemental Health,” forthcoming in *Healthcare Transformation: Artificial Intelligence, Automation and Robotics*.
- 170.D.G. Stevenson, N. Sinclair, S. Zhang, L. Meneades, and **H.A. Huskamp**. “Trends in Contracting and Common Ownership between Hospice Agencies and Nursing Homes,” *Medical Care* 58(4):329-335, (2020).
- 171.M.L. Barnett and **H.A. Huskamp**, “Telemedicine for Mental Health in the U.S.: Making Progress, Still a Long Way to Go,” *Psychiatric Services* 71(2):197-98, (2020).
- 172.L. Uscher-Pines, P. Raja, N. Qureshi, **H. Huskamp**, A. Busch, A. Mehrotra, “Use of Telemental Health in Conjunction with In-Person Care: A Qualitative Exploration of Implementation Models,” forthcoming in *Psychiatric Services* 71(5):419-426, (2020).
- 173.S.B. Dusetzina, **H.A. Huskamp**, S.A. Jazowski, A.N. Winn, W.A. Wood, A. Olszewski, E. Basch, and N.L. Keating, “Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancers,” *Journal of the National Cancer Institute* (10):1055-1062, (2020).
- 174.L. Uscher-Pines, **H.A. Huskamp**, and A. Mehrotra, “Treating Patients with Opioid Use Disorder in Their Homes: An Emerging Treatment Model,” *JAMA* 324(1):39-40, (2020).
- 175.S. Patel, **H.A. Huskamp**, A.B. Busch, and A. Mehrotra, “Telemental Health and U.S. Rural-Urban Differences in Specialty Mental Health Use, 2010-2017,” *American Journal of Public Health* 110(9):1308-14, (2020).
- 176.S.B. Dusetzina, **H.A. Huskamp**, L.M. Keohane, and N.L. Keating, “Medicare Part D and Insulin Affordability – The Devil is in the Details,” *New England Journal of Medicine* 382(20):1878-80, (2020)

- 177.L.G. Gilstrap, R.A. Blair, **H.A. Huskamp**, K. Zelevinsky, and S-L. Normand, "Assessment of Second-generation Diabetes Medication Initiation among Medicare Enrollees from 2007 to 2015," *JAMA Network Open*, 3(5):e205411, (2020).
- 178.A.B. Busch, S.F. Greenfield, S. Reif, S.T. Normand, and **H.A. Huskamp**, "Outpatient Care for Opioid Use Disorder among the Commercially Insured: Use of Medication and Psychosocial Treatment," *Journal of Substance Abuse Treatment*, Aug;115:108040, (2020).
- 179.L. Uscher-Pines, P. Raja, A. Mehrotra, and **H.A. Huskamp**, "Health Center Implementation of Telemedicine for Opioid Use Disorders: A Qualitative Assessment of Adopters and Nonadopters," *Journal of Substance Abuse Treatment*, Aug;115:108037, (2020).
- 180.K.W. Scott, M.G. Findling, **H.A. Huskamp**, J.W. Scott, J.M. Benson, K.E. Kocher, and R.J. Blendon, "Differences between Emergency Department and Urgent Care Users for Low-Acuity Health Needs: A Public Opinion Analysis," *Academic Emergency Medicine* 28(2):240-243, (2021).
- 181.**H.A. Huskamp**, S. Reif, S.F. Greenfield, S.-L.T. Normand, and A.B. Busch, "Medication Utilization for Alcohol Use Disorder in a Commercially-Insured Population," *Journal of General Internal Medicine* 35(11):3262-3270, (2020).
- 182.C. Gu, **H. Huskamp**, J. Donohue, and S-L.T. Normand, "A Bayesian Hierarchical Model for Characterizing the Diffusion of New Antipsychotic Drugs," forthcoming in *Biometrics*.
- 183.S.Y. Patel, A. Mehrotra, **H.A. Huskamp**, L. Uscher-Pines, I. Ganguli I, and M.L. Barnett, "Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the United States," *JAMA Internal Medicine* 181(3):388-391, (2021).
- 184.S.B. Dusetzina, B. Muluneh, N.L. Keating, and **H.A. Huskamp**, "Broken Promises -- How Medicare Part D Has Failed to Deliver Savings to Older Adults," *New England Journal of Medicine* 383(24):2299-2301, (2020).
- 185.A. Cuellar, T.L. Mark, S.S. Sharfstein, and **H.A. Huskamp**, "How to Mitigate the Mental Health Care Consequences of the COVID-19 Financial Crisis," *Psychiatric Services* 71(12):1317-1319, (2020).
186. L. Uscher-Pines, J. Sousa, P. Raja, A. Mehrotra, M. Barnett, and **H.A. Huskamp**, "Treatment of Opioid Use Disorder during COVID-19: Experiences of Clinicians Transitioning to Telemedicine," *Journal of Substance Abuse Treatment*, Nov;118:108124, (2020).
- 187.L. Uscher-Pines, J. Cantor, **H.A. Huskamp**, A. Mehrotra, A. Busch, and M. Barnett, "Adoption of Telemedicine Services by Substance Abuse Treatment Facilities in the U.S.," *Journal of Substance Abuse Treatment*, Oct;117:108060, (2020).

188. L. Uscher-Pines, J. Sousa, P. Raja, A. Mehrotra, M.L. Barnett, and **H.A. Huskamp**, “Suddenly Becoming a ‘Virtual Doctor’: Experiences of Psychiatrists Transitioning to Telemedicine during the COVID-19 Pandemic,” *Psychiatric Services* 71(11):1143-50, (2020).
189. **H.A. Huskamp**, A.B. Busch, L. Uscher-Pines, M.L. Barnett, L. Riedel, and A. Mehrotra, “Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic,” *JAMA* 324(23):2440-2442, (2020).
190. L. Chen, R.G. Frank, and **H.A. Huskamp**, “Overturning the ACA’s Medicaid Expansion Would Likely Decrease Low-Income Reproductive-Age Women’s Healthcare Spending and Utilization, forthcoming in *Inquiry*, Jan-Dec;57:46958020981462, (2020).
191. A. McDowell A, **H.A. Huskamp**, A.B. Busch, A. Mehrotra, and S. Rose, “Patterns of Mental Health Care Prior to Initiation of Telemental Health Services,” forthcoming in *Medical Care*, Apr 1. doi: 10.1097/MLR.0000000000001537, (2021).
192. S.Y. Patel, A. Mehrotra, **H.A. Huskamp**, L. Uscher-Pines, I. Ganguli, and M.L. Barnett, “Variation in Telemedicine Use and Outpatient Care during the COVID-19 Pandemic in the United States,” *Health Affairs* 40(2):349-358, (2021).
193. S.B. Dusetzina, **H.A. Huskamp**, S.A. Jazowski, A.N. Winn, E. Basch, and N.L. Keating, “Comparison of Anticancer Medication Use and Spending Under United States Oncology Parity Laws With and Without Out-of-Pocket Spending Caps,” forthcoming in *JAMA Health Policy Forum*.
194. S.B. Dusetzina, N.L. Keating, and **H.A. Huskamp**, “Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access,” *JAMA Internal Medicine* 181(4):423-424, (2021).
195. S.Y. Patel, S. Rose, M.L. Barnett, **H.A. Huskamp**, L. Uscher-Pines, and A. Mehrotra, “Community Factors Associated with Telemedicine Use During the COVID-19 Pandemic,” *JAMA Network Open*, May 3;4(5):e2110330, (2021).
196. S.Y. Patel, **H.A. Huskamp**, M.L. Barnett, J.R. Zubizarreta, A.B. Busch, K. Zachrisson, A.D. Wilcock, and A. Mehrotra, “Association between Telepsychiatry Capability and Treatment of Patients with Mental Illness in the Emergency Department,” forthcoming in *Psychiatric Services*.
197. A. Kennedy-Hendricks, C.J. Schilling, A.B. Busch, E.A. Stuart, **H.A. Huskamp**, M.K. Meiselbach, C.L. Barry, and M. Eisenberg, “Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder,” forthcoming in *Journal of General Internal Medicine*.
198. L. Riedel, L. Uscher-Pines, A. Mehrotra, A.B. Busch, M.L. Barnett, P. Raja, **H.A. Huskamp**. “Use of Telemedicine for Opioid Use Disorder Treatment – Perceptions and Experiences of Opioid Use Disorder Clinicians,” forthcoming in *Drug and Alcohol Dependence*.

199. S.B. Dusetzina, A. Sarpatwari, M.A. Carrier, R.A. Hansen, N.L. Keating, and **H.A. Huskamp**, “Patient and Payer Incentives to Use On-Patent Brand-Name Drugs Over Authorized Generics in Medicare Part D,” forthcoming in *JAMA Internal Medicine*.
200. T.J. Hwang, X. Qin, N.L. Keating, **H.A. Huskamp**, and S.B. Dusetzina, “Assessment of Out-of-Pocket Costs with Rebate Pass-Through for Brand-Name Cancer Drugs Under Medicare Part D,” forthcoming in *JAMA Oncology*.
201. **H.A. Huskamp**, L. Riedel, L. Uscher-Pines, A.B. Busch, M.L. Barnett, P. Raja, and A. Mehrotra, “Initiating Opioid Use Disorder Medication via Telemedicine during COVID-19: Implications for Proposed Reforms to the Ryan Haight Act,” forthcoming in *Journal of General Internal Medicine*.
202. C.J. Schilling, M.D. Eisenberg, A. Kennedy-Hendricks, A.B. Busch, **H.A. Huskamp**, E.A. Stuart, M.K. Meiselbach, and C.L. Barry, “Effects of High-Deductible Health Plans on Enrollees with Mental Health Conditions with and without Substance Use Disorders,” forthcoming in *Psychiatric Services*.
203. B.A. Barsky, A.B. Busch, S.Y. Patel, A. Mehrotra, and **H.A. Huskamp**, “Use of Telemedicine for Buprenorphine Inductions in Patients with Commercial Insurance,” forthcoming in *JAMA Network Open*.
204. M.D. Eisenberg, A. Kennedy-Hendricks, C. Schilling, A. Busch, **H.A. Huskamp**, L. Stuart, M. Meiselbach, and C.L. Barry, “The Impact of High-Deductible Health Plans on Substance Use Disorder Treatment Use and Spending,” forthcoming in *American Journal of Managed Care*.
205. **H.A. Huskamp**, J.L. Kim, and D.G. Stevenson, “Concurrent Use of Opioids and Benzodiazepines among Nursing Home and Assisted Facility Residents Who Receive a Pain Medication,” forthcoming in *Journal of the American Geriatric Society*.
206. D.G. Stevenson, A.B. Busch, B.J. Zarowitz, and **H.A. Huskamp**, “Psychotropic and Pain Medication Use in Nursing Homes and Assisted Living Facilities during COVID-19,” forthcoming in *Journal of the American Geriatric Society*.

### Reviews, Chapters, and Editorials

1. **H.A. Huskamp**, “Managed Behavioral Health Care Carve-out RFPs and Contracts for Individuals with Severe Mental Illness,” monograph prepared for the National Alliance for the Mentally Ill, (1996).
2. R. Conti, E. Dorosh, A.M. Epstein, R.G. Frank, **H.A. Huskamp** and M.B. Rosenthal, “Drug Policy Issues in California,” monograph prepared for the California Health Care Foundation, (1999).
3. **H.A. Huskamp**, Comment on Sensenig A. and Wilcox E. “National Health Accounts/National Income and Product Accounts Reconciliation,” Chapter 7 in *Medical Care Output and Productivity*, edited by David M.



Cutler and Ernst R. Berndt, National Bureau of Economic Research, Studies in Income and Wealth, Volume 62, pp. 300-302 (2001).

4. **H.A. Huskamp** and N.L. Keating, “The New Medicare Drug Benefit: Potential Effects of Pharmacy Management Tools on Access to Medications,” Henry J. Kaiser Foundation, July 2004.
5. D.G. Stevenson, **H.A. Huskamp**, and Joseph P. Newhouse, “Medicare Part D, Nursing Homes, and LongTerm Care Pharmacies,” report to the Medicare Payment Advisory Commission, March 2007.
6. **H.A. Huskamp**, T. Sussman Oakman, and D.G. Stevenson, “Medicare Part D and Its Impact on the Nursing Home Sector: An Update,” report to the Medicare Payment Advisory Commission, March 2010.
7. **H.A. Huskamp** and C.L. Barry, “Can New Payment and Delivery System Models Achieve High Value Care for Mental Health and Substance-Use Disorders,” *New England Journal of Medicine* and *Harvard Business Review* Leading Health Care Innovation Series, 2013.
8. C. Barry, L. Riedel, A. Busch, and **H. Huskamp**, “Early Insights from One Care: Massachusetts’ Demonstration to Integrate Care and Align Financing for Dual Beneficiaries,” May 12, 2015, <http://kff.org/medicaid/issue-brief/early-insights-from-one-care-massachusetts-demonstration-to-integratecare-and-align-financing-for-dual-eligible-beneficiaries/>
9. **H.A. Huskamp** and D.G. Stevenson, “Financing Care at the End of Life and the Implications of Potential Reforms,” in Institute of Medicine of the National Academies’ “Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life,” The National Academies Press, Washington, D.C., 2015.
10. D.G. Stevenson and **H.A Huskamp**, “Hospice Payment Reforms Are a Modest Step Forward, But More Changes are Needed,” Health Affairs Blog, January 4, 2016, <http://healthaffairs.org/blog/2016/01/04/hospice-payment-reforms-are-a-modest-step-forward-but-morechanges-are-needed/print/>
11. **H.A. Huskamp** and D.G. Stevenson, “Financing Care at the End of Life: Ensuring Access and Quality in an Era of Value-Based Reforms,” in Improving Care at the End of Life: A Report of the Aspen Institute Health Strategy Group, 2016, <https://assets.aspeninstitute.org/content/uploads/2017/02/AHSG-ReportImproving-Care-at-the-End-of-Life.pdf>
12. **H.A. Huskamp**, “Mental Health Insurance Parity: How Full is the Glass,” in Handbook of Mental Health Policy, eds. R.G. Frank, H.H. Goldman, and J. Morrissey, 2019.

## **Report**

Haiden Huskamp, Ph.D., is a health economist and the Henry J. Kaiser Professor of Health Care Policy. Dr. Huskamp has three primary areas of research: 1) mental health and substance use disorder policy; 2)

prescription drug policy; and 3) the financing and utilization of end-of-life care services. She also serves as Director of Harvard's National Institute of Mental Health (NIMH) T32 Pre- and Post-doctoral Training Program in Mental Health Policy.

Dr. Huskamp is Multi-Principal Investigator (MPI) on an R01 funded by the National Institute on Drug Abuse (NIDA) assessing the use of telemedicine for the treatment of opioid use disorder. She also serves as MPI on an R01 funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) on the prescribing and use of medications that treat alcohol use disorder. Dr. Huskamp recently served as MPI for an R01 funded by the NIMH focused on factors that influence physician adoption and use of antipsychotic medications and an R01 funded by NIDA assessing the effects of new payment and delivery models on substance use disorder treatment. Dr. Huskamp is currently studying utilization of substance use disorder treatments among enrollees in high deductible health plans. She has published numerous papers on the impact of managed care for behavioral health services on utilization patterns, costs, and quality of care and on the impact of parity in insurance coverage for behavioral health services. Dr. Huskamp previously served as a member of the Institute of Medicine Committee on Developing Evidence-Based Standards for Psychosocial Interventions for Mental Disorders. She is a co-Director for the Brandeis-Harvard NIDA Center to Improve System Performance of Substance Use Disorder Treatment.

Dr. Huskamp is an expert on the impact of pharmacy management tools used to control prescription drug costs on drug utilization, cost, and quality of care. Through a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, Dr. Huskamp examined the social costs and benefits of newer psychotropic drugs to assess their social value and identify ways that the value of psychotropic drug spending can be increased. She previously served as MPI on a NIMH-funded U01 grant examining characteristics of provider organizations that influence the diffusion of new technologies, including prescription drugs. Dr. Huskamp served as a member of the Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Products Development.

Dr. Huskamp's research on end-of-life care has examined the changing characteristics of the hospice industry and the effects of industry changes on the provision of end-of-life care, the timing of discussions about hospice care that occur between physicians and patients with advanced illness, and variation in hospice costs across hospice users. She served as a member of the Institute of Medicine Committee on Care for Children Who Die and Their Families, and she currently serves on the National Academy of Medicine Roundtable on Quality Care for People with Serious Illness.